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Gender and Cocaine Use Influence the Expression of Urinary Markers of Inflammation 
and Oxidative Stress 
Marie Meagher Bourgeois 
Abstract 
 
The purpose of this study was to investigate whether or not gender differences 
may be present in the expression of a number of urinary proteins which may serve as 
markers of inflammation and oxidative stress. Males and females have different patterns 
of illness and different life spans, suggesting basic biological traits exert significant 
control on the incidence of rhabdomyolysis, renal failure, atherosclerosis, myocardial 
ischemia, myocardial contraction band formation, autoimmune disorders and general 
inflammatory diseases.  Men are at greater risk for cardiovascular disease; however 
women, particularly elderly women, have higher fatality rates due to heart failure. Renal 
diseases progress far more quickly in men, possibly due to testosterone. Men also have 
higher kidney bulk related to androgen expression. Gender disparity may be most 
obvious in autoimmune disorders; of the estimated 8.5 million people diagnosed with 
autoimmune disorders, approximately 80% are women. Hashimoto’s thyroiditis, the most 
common form of hypothyroidism, is up to 10 times more common in women. Systemic 
Lupus Erythematosus (SLE), an autoimmune disease characterized by acute and chronic 
inflammation, is 9 times more common in women. Rheumatoid arthritis (RA), an 
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autoimmune disease affecting approximately 1.3 million people in the United States, is 
four times more common in women. Diabetes mellitus (DM), affecting more than 17 
million people – the majority of which are women, is linked to microvascular and 
macrovascular diseases such as kidney failure, strokes and atherosclerosis. These 
conditions are linked to physiological changes that may alter the expression of certain 
biomarkers of inflammation and oxidative stress.  
Over the past several decades, it has become increasingly clear that the role of 
diet, smoking, and other lifestyle choices clearly influence the etiology and 
pathophysiology of these diseases. The use of drugs, both licit and illicit, has been clearly 
linked to many of these diseases. Illicit substances, particularly cocaine, have been 
demonstrated to produce pathophysiological changes to many systems in the body which 
can greatly influence the progression of existing and drug-induced disease states leading 
to systemic damage.  A relationship between the expression of markers of inflammation, 
oxidative stress, cardiac damage, or other systemic injury, gender and cocaine use has not 
been clearly established.  
Urine is an important medium for assessment of general health status. It has 
classically been used to monitor disease states; glucosuria as an indicator of diabetes and 
renal dysfunction, microorganisms signifying urinary tract or bladder infection, and 
biomarkers such as human chorionic gonadotropin to confirm pregnancy. Recently urine 
has been used to assess biomarker expression and disease states.  Urine is an ideal clinical 
tool for toxicological screens; it is readily accessible, non invasive and typically supplied 
in sufficient quantity to accommodate multiple tests. In this study, urine specimens were 
collected and analyzed for creatinine, cocaine, total protein, aldosterone, c-reactive 
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protein (hsCRP), myeloperoxidase (MPO), microalbumin (MAB), neutrophil gelatinase-
associated lipocalin (NGAL), heat shock protein 90α (hsp90α), vascular endothelial 
growth factor (VEGF), myoglobin, pro atrial natriuretic peptide (proANP) and 
interleukins 1α, 1 β , and 6 using ELISA and colorimetric assays.  
 Urine specimens that tested negative for all illicit substances in the standard 
National Institute on Drug Abuse (NIDA) 10 panel showed differences in a number of 
these biomarkers which strongly suggested significant differences between males and 
females for aldosterone, IL1α and IL1β.  In addition, significance is suggested for MPO 
and CRP. Although sex specific differences in serum expression have been noted for 
some of the markers in both animal and human models, this has not been previously 
demonstrated in human urine. This may have implications for what is typically referred to 
as ‘normal’ values.  Gender specific differences were not apparent in urine specimens 
that tested positive for cocaine. Also, in males only, the levels of myoglobin and 
aldosterone significantly increased.  
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Chapter 1.0 
Introduction 
 
In 2001, the Institute of Medicine stated that gender is a „basic human variable‟ 
that should be considered in every facet of research design [1]. Significant gender 
dimorphism has been documented in cardiovascular, renal and autoimmune diseases [2-
8]. Higher male susceptibility to cardiovascular disease may be
 
due to genetic, hormonal, 
or lifestyle factors or through a combination
 
of mechanisms [9, 10]. Sex-based 
differences in the clinical presentation, diagnosis, and
 
treatment outcomes of cardiac 
disease have long been recognized  [11]. Gender differences in lifestyle risk factors (e.g. 
smoking, exercise and diet) appear to contribute to
 
gender disparities; however, these 
lifestyle factors do not completely account for the dimorphism. Despite the fact that there 
is a higher incidence of cardiovascular diseases in men in general, the total number of 
deaths from cardiovascular
 
disease has been higher for women than for men [12]. 
Coronary artery disease is the leading cause of death in women. More than twice as many 
women die from cardiovascular disease as from all forms of cancer combined. Men are 
more likely than women to suffer from hypertension. Multiple physiological alterations 
have been noted in hypertensive individuals; these include renal disturbances, 
neurohormonal and adrenergic disruption, endothelial dysfunction, systemic 
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inflammation, and increased oxidative stress. Increased creatinine, CRP, aldosterone and 
proANP are often seen in hypertension. CRP is an acute phase inflammatory marker 
considered indicative of atherosclerosis and AMI. ProANP is found in atrial myocytes 
and regulates blood pressure by opposing aldosterone. Proteinuria is common in renal 
and cardiovascular disease. Elevated urine protein concentrations are linked to increased 
IL 6 production and heart failure. MPO is another inflammatory marker; it is used to 
predict the risk of AMI in the absence of cardiac necrosis. Hsp90α, a cytosolic chaperone 
molecule found in cardiac tissue, is linked to oxidative stress.  It is inhibited by estradiol 
(E2). VEGF is inducible by ischemia and anoxia; it is often elevated along with 
microalbumin. Microalbuminuria is associated with cardiovascular disease. It is induced 
by vasodilation and hypoxia-inducible factors. E2 promotes vasodilation. Myoglobin is 
the first marker released following myocardial necrosis and cardiac dysfunction. IL1 α 
and IL1β are proinflammatory cytokines stimulated by hepatic acute phase cytokines 
such as CRP that induce IL6. Another example of gender influence can be seen in the 
prevalence and progression of many renal diseases [4, 13].   
The majority of chronic renal diseases occur more commonly in men and progress 
far more quickly. There is no discernible gender disparity in acute kidney disease rates. 
Chronic Kidney Disease (CKD) is one of the few chronic renal diseases that occur more 
commonly in women. CKD can lead to End Stage Renal Disease (ESRD) if it is not 
treated. The physiology behind gender differences in renal disease is unclear, but 
differences in kidney size and physiology, coupled with lifestyle factors and the 
vasoprotective effects of estrogen, have been implicated [1, 14-19]. Estrogen is thought 
to suppress the growth of renal scar tissue by inhibiting the production of collagen.  
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Interestingly, this female advantage in chronic kidney disease disappears when the 
women suffer from diabetes mellitus (DM). CKD is uncommon in premenopausal 
women. The rate of CKD increases as estrogen levels fall; however, this may be the 
result of the relative ratio of androgen to estrogen rather than the absolute level of 
estrogen. It is thought that the androgen to estrogen ratio determines the effect on the 
diabetic kidney. Unlike their non-diabetic counterparts, women with DM are found to 
have similar rates of kidney disease as males. DM is an increasingly common cause of 
kidney failure in developed countries. Increased renin–angiotensin system (RAS) activity 
is thought to play an important role in both the hemodynamic and nonhemodynamic 
pathways involved in organ damage, particularly for diabetes. RAS blockade has 
demonstrated nephroprotective properties in diabetic individuals. Two mechanisms for 
promoting vasoconstriction are RAS activation and nitric oxide (NO) pathway disruption. 
Hyperglycemia disrupts NO-mediated relaxation; despite this interaction, baseline renal 
vasodilation is common in diabetes [20]. Hypertension is common in diabetics; increased 
aldosterone concentration in urine is a risk factor for renal disease. Creatinine can be used 
to assess glomerular filtration rate. Increased concentrations are seen in DM, 
hypertension and impaired renal function. Normal urine does not have substantial protein; 
proteinuria is considered suggestive of renal disease. Microalbuminuria is often seen in 
renal dysfunction, as is elevated VEGF. Myoglobinuria is common in rhabdomyolysis 
and renal failure. CRP and MPO, inflammatory markers, are often elevated in renal 
disease. NGAL is the earliest responding marker in acute kidney injury; it is also elevated 
in CKD, some forms of lupus and urinary tract infections. Hsp90α, induced by heat 
shock, inflammation and oxidative stress, is often upregulated by renal disease. IL1 α and 
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IL1 β, endogenous pyrogens, may be elevated in cases of renal disease. IL 6 acts 
synergistically with both IL1 subunits. The interleukins may also be elevated in 
autoimmune disorders. 
A common feature of autoimmune diseases in both humans and experimental 
animals is that females are far more susceptible to autoimmune conditions when 
compared to males. In several animal models, estrogens promote B cell mediated 
autoimmune diseases. Androgens exert an inhibitory effect in the same models. Although 
the reason is unclear, females tend to secrete higher levels of interleukins such as IL1 α 
and IL1 β. Females display heightened immune responses not only to foreign antigens 
but also to self-antigens. Estrogens induce T and B cells imbalances; they appear to 
induce hypoactivity in subsets of T cell and hyperactivity in B cells. This may be the 
underlying basis for estrogen induced autoimmunity. Of the 8.5 million Americans 
diagnosed with autoimmune disorders, approximately 80% are women [21]. Rheumatoid 
arthritis (RA) is 4 times more common in women, systemic lupus erythematosus (SLE) is 
nine times more common in women and some forms of thyroiditis are 10 times more 
common in women compared with men [22, 23]. Insulin dependent DM is also more 
common in women than it is in men. Studies have shown that a disparity exists between 
male and female diabetics, particularly in the control of modifiable risk factors such as 
blood pressure, serum glucose and cholesterol levels [16, 24]. Some researchers believe 
this is why death due to heart disease has decreased among diabetic men but not in 
women. Creatinine is often elevated in DM. CRP and MPO may be elevated in cases of 
inflammatory immune diseases such as RA and SLE. CRP may be a surrogate marker of 
SLE activity and may be useful to monitor the course of the disease. NGAL often 
 5 
 
increases in tandem with MPO. Hsp90α, upregulated by oxidative stress and 
inflammation, may increase with autoimmune disease. VEGF is another cytokine 
inducible by inflammation. Myoglobinuria may be seen in DM and other autoimmune 
disease. Subclinical inflammatory reaction has been shown to precede DM; IL1 α, IL 1 β, 
and IL6 are inflammatory cytokines. Studies have shown that systemic injection of IL1α 
and IL1 β induces the symptoms of systemic inflammation (e.g. fever, joint pain, 
headaches, neutrophilia and increases in circulating cytokines). Systemic and chronic 
inflammation are thought to contribute to the development of atherosclerosis and CHD. 
The plurality of these conditions has been linked to inflammation and oxidative stress and 
may result in the release of biomarkers into blood and other body fluids [2-4, 13, 22, 23, 
25-30]. 
Inflammation is one of the most prominent forms of oxidative damage. Reactive 
oxygen species (ROS) produced by endothelial cells, neutrophils and macrophages can 
stimulate the activation of proinflammatory transcription factors and induce the 
production of inflammatory cytokines such as IL1 and IL6. Inflammation begins with 
hyperemia, edema, and adherence of the circulating white blood cells to endothelial cells. 
Local inflammatory response is typically accompanied by systemic changes that include 
hyperemia, leukocytosis, and induction of acute-phase reactants like CRP. Chronic 
inflammation is not confined to a particular tissue; it involves the endothelium and 
multiple organ systems. High levels of oxidative stress and inflammation can increase the 
probability of early incidence of multiple disease states, including atherosclerosis, 
Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, fragile X 
syndrome and chronic fatigue syndrome (Figure 1).   
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Figure 1. Conditions Associated with Inflammation and Oxidative Stress 
 
Oxidative stress (OS) describes the level of oxidative damage in a cell, tissue, or 
organ, caused by ROS. The damage can affect everything from specific molecules to 
entire organisms. ROS such as free radicals and peroxides come from the metabolism of 
oxygen and are endogenous in all aerobic organisms. The rate at which damage occurs is 
primarily determined by the clearance of generated ROS by antioxidants. The rate of 
damage depends on the level of repair enzyme. Most are by-products of essential 
metabolic reactions such as mitochondrial energy generation and hepatic cytochrome P-
450 detoxification reactions. Exogenous sources of ROS include lifestyle choices 
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(cigarette smoking, alcohol consumption, dietary, etc.), environmental exposures 
(automotive emissions, industrial pollutants, asbestos, etc.), bacterial, fungal or viral 
infections and radiation. Exercise has the potential to induce free radical formation 
leading to OS [31]. Much of the damage associated with cocaine toxicity stems from OS 
[32].  In addition to environmental and lifestyle exposures, the determinants of oxidative 
stress are regulated by hereditary factors. Oxidative stress is also implicated in the 
ischemic cascade in reperfusion injuries. Myoglobin from myolysis, common with 
syndromes like rhabdomyolysis, may cause OS [33]. ROS are not uniformly destructive; 
they are used by the immune system as a way to attack and kill pathogens and in redox 
signaling. 
Cocaine (benzoylmethylecgonine) is an alkaloid derived from the leaves of 
Erthroxylon coca, a shrub indigenous to South America [34]. Despite restrictions on 
importation and distribution, cocaine has become one of the most commonly used illicit 
drugs [35]. According to the 2007 National Survey on Drug Use and Health, nearly 1.6 
million Americans met Diagnostic and Statistical Manual of Mental Disorders criteria for 
dependence or abuse of cocaine (in any form) in the past 12 months. The 2005 Drug 
Abuse Warning Network (DAWN) report stated that cocaine was involved in 448,481 of 
the total 1,449,154 (31%) visits to emergency departments (ED) for drug misuse or 
abuse. Cocaine is the most frequently reported illicit drug associated with ED admissions 
[36]. Cocaine is a powerful sympathomimetic capable of vasoconstriction and increasing 
heart rate, blood pressure, contractility, respiration, myocardial oxygen demand and body 
temperature [37]. Hyperpyrexia can lead to rhabdomyolysis, myoglobulinuria, renal 
failure, liver damage and disseminated intravascular coagulation [38]. Cocaine use is 
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linked to atherosclerosis, myocardial ischemia, myocardial contraction band formation 
and sudden death [36, 39]. Cocaine-induced chest pain is the most common symptom 
reported by patients; an estimated 64,000 patients were evaluated for myocardial 
ischemia in 1995 subsequent to cocaine-related chest pain [40, 41]. Some of these 
patients exhibited elevated CK-MB levels or electrocardiogram (ECG) changes 
consistent with acute myocardial infarction (AMI); however, the majority reported 
recurrent chest pain subsequent to cocaine use following discharge [41, 42]. 
 The metabolism of cocaine is primarily hepatic, with only about 1% excreted 
unchanged in the urine [43]. Cocaine has two primary metabolic pathways in humans, 
deesterification and demethylation. Benzoylecgonine (BE) is the primary metabolite and 
is not considered an important source of ROS. Ecgonine methyl ester (EME) is the 
second most common metabolite. Neither BE nor EME are biologically active. 
Transmethylation of cocaine is a minor pathway; metabolites of this pathway include 
norcocaine, norcocaine nitroxide, n-hydroxynorcocaine and formaldehyde. Microsomes 
in the brain and liver oxidize norcocaine to nitroxide. Microsomal reduction of 
norcocaine nitroxide in the brain generates superoxide (SO) [32]. Hepatic microsomes 
incubated with nitroxide or the N-hydroxy derivative results in lipid peroxidation [27].  
Transesterification of cocaine occurs in the presence of alcohol and produces the 
biologically active intermediate cocaethylene. Various cocaine related hepatotoxicity 
studies indicate the generation of ROS, including lipid peroxides [44, 45]. Cocaine has 
been shown to induce the release of SO which has been implicated in cardiac and 
cerebrovascular dysfunction [32]. 
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 The vasoconstriction associated with cocaine usage is thought to result from its 
blockade of norepinephrine and dopamine reuptake at preganglionic sympathetic nerve 
endings; the extended catecholamine presence increases heart rate and blood pressure 
[40, 46]. Cocaine also disrupts catecholamine metabolism by inhibiting monoamine 
oxidase (MAO). By blocking the neuronal plasma membrane transporter, cocaine 
increases extracellular levels of monoamines [47]. Hypertension is associated with 
disruptions in endothelial cell function and oxidative stress. MPO promotes endothelial 
dysfunction [48]. Microalbumin is inducible by endothelial dysfunction and oxidative 
stress; cocaine use may impact expression of this marker [49]. IL1α and IL1β are induced 
by increased body temperature [50]. Cocaine is a known hyperpyrexic so it is possible 
that usage could result in increases in the concentrations of these markers [51].  Oxidative 
stress has also been implicated as an early triggering event of cocaine-induced 
cardiomyopathy and atherosclerosis [52] . IL6, CRP and MPO are being considered for 
validation as cardiac biomarkers [48, 53]. MPO has also been linked to the pathogenesis 
of renal injury [54, 55]. Increased expression of these cytokines may result from cocaine-
induced atherosclerosis and other cardiac disruptions. Fluctuations in blood pressure 
activate the renin-angiotensin system RAS which may increase proANP expression along 
with aldosterone production. RAS activation contributes to OS and vascular 
inflammation; it can also change the baseline filtering activity of the kidneys. 
Aldosterone stimulates inflammation through ROS generation. Cocaine use is linked to 
both renal dysfunction and rhabdomyolysis [34, 56]. NGAL is a validated marker for 
acute kidney damage and inflammatory processes [57]. Myoglobinuria, proteinuria and 
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increased expression of creatinine are associated with rhabdomyolysis and cardiac 
dysfunction; both conditions may result from cocaine use [53, 58]. 
The link between biomarker expression in urine and gender or cocaine-based 
inflammation, cardiac damage, or other systemic injury has not been elucidated. Urine 
samples were assayed for benzoylecgonine (BE), total protein, aldosterone, c-reactive 
protein (CRP), myeloperoxidase (MPO), microalbumin (MAB), neutrophil gelatinase-
associated lipocalin (NGAL), heat shock protein 90α (hsp90α), vascular endothelial 
growth factor (VEGF), myoglobin, pro atrial natriuretic peptide (proANP) and 
interleukins 1α, 1 β, and 6 using ELISA and colorimetric assays; these markers were 
selected for their biological plausibility and assay kit availability. Urine is a non invasive 
specimen typically provided in sufficient quantity to allow multiple tests. As most 
toxicological screens primarily utilize urine specimens in clinical settings, we examined 
the possibility of establishing relationships between the expression of several urinary 
biomarkers associated with oxidative stress and inflammation and gender and cocaine 
use. 
The following hypotheses were tested in this study:  
1. The expression of some urinary markers of inflammation and/or oxidative stress is 
influenced by gender. Creatinine and myoglobin are related to lean muscle mass; 
therefore, males should have higher urinary mean concentrations. Total protein, 
microalbumin and NGAL may be elevated in females as they suffer far more urinary tract 
infections than males. IL1α, IL1β, IL6, MPO, VEGF and CRP may be higher in females 
as they suffer disproportionately from autoimmune/inflammatory diseases. 
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2. The expression of these markers is influenced by the use of cocaine. Creatinine and 
myoglobin are increased by hyperthermia and rhabdomyolysis; therefore, cocaine 
positive specimens should have a higher mean values than control urine specimens. 
Cocaine induces oxidative stress and inflammation; aldosterone, myoglobin, VEGF, 
NGAL, IL1α, IL1β, IL6, MPO and CRP may be higher in cocaine positive specimens. 
Hsp90α and proANP are associated with cardiac dysfunction; they may be higher in 
cocaine positive specimens.  
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Chapter 2.0 
Literature Review 
 
2.1 Gender 
 
There are significant gender based differences in the etiology of disease states 
including cardiac and vascular disease, metabolic disorders, autoimmune disorders and 
drug abuse toxicology. The basis of the gender dimorphism is unclear; however, cardiac 
muscle and vascular tissue are influenced by hormones such as estrogen and testosterone 
[1, 9, 10, 12, 59-61]. Premenopausal women appear to be partially protected to some 
extent from cardiovascular and kidney diseases; however, this protection weakens after 
menopause [62]. Gender differences may exist not only in atherogenesis but also in post 
ischemic/infarction cardiovascular repair. Angiogenesis is essential to cardiovascular 
repair and regeneration. The effect of estrogen on angiogenesis has been extensively 
studied, but the role of androgens remains unexplored [63]. Estrogens induce vasodilation 
by increasing the activity of endothelial nitric oxide synthase (eNOS).  
Estrogens and androgens regulate the RAS which in turn regulates the 
cardiovascular system and the kidneys [64]. In general, estrogen decreases renin 
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production thereby decreasing aldosterone production. Progesterone competes with 
aldosterone for mineralocorticoid receptor. Aldosterone is linked to inflammation via 
ROS generated oxidative stress. Aldosterone is a renal hormone in the RAS secreted in 
response to hypotension. Aldosterone has been implicated in renal disease progression; 
the majority of renal diseases are far more common in men. Increased cardiac 
concentrations have been linked to heart failure. Creatinine is also a general marker of 
muscle and kidney disease [18, 19]. Because creatinine is related to lean muscle mass, 
men tend to have slightly higher serum creatinine levels than do women. Increased 
vascular oxidative stress leads to endothelial dysfunction and hypertension. Inhibition of 
the RAS results in a decline in ROS production [65, 66]. Estrogen also activates 
natriuretic peptides such as proANP; these peptides are a counterpart of the RAS. 
Testosterone seems to exert the opposite effect on renin levels. These effects of sex 
hormones on the RAS may explain some of the gender differences in cardiovascular and 
kidney diseases [67].  
Exposure to sex hormones modulates many endocrine factors involved in 
atherosclerosis. Increased vascular oxidative stress leads to endothelial dysfunction and 
hypertension. It has been noted that inhibition of the RAS results in a decline in ROS 
production [65, 66]. Studies suggest females are at lower risk of developing 
cardiovascular disease (CVD) as compared to males [68]. Striking sex differences exist 
not only in the incidence of cardiovascular disease, but also in the clinical outcomes. 
Cardiovascular events occur earlier in men than in women; however, it appears women 
have poorer short-term and long-term outcomes following these events compared to men. 
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Autoimmune disorders may contribute to the gender based differences in cardiac 
outcomes; for example, RA, far more common in women, is associated with a higher 
prevalence and higher severity of atherosclerosis [69]. 
Autoimmune diseases are the third most common category of disease in the 
United States after cancer and heart disease. Male and female immune response differs; 
women mount more vigorous immune responses with increased antibody production 
[70]. Women also have far higher autoimmune disease rates [71, 72]. When men develop 
autoimmune diseases, they are often more severe. Many animal models of autoimmune 
disease have shown a similar sex bias, with a higher incidence of disease in females [73-
77]. Estrogen, testosterone, and progesterone are thought to mediate most of the sex-
biased differences in the immune response [78, 79]. Cytokine receptors such as 
interleukin 1 receptor (IL-1R) have been discovered on hormone-producing tissues. 
Proinflammatory cytokines such as IL-1α and IL-1β stimulate the release of 
glucocorticoids which regulates the inflammatory process along with androgens and 
estrogens. Estrogen significantly increases proinflammatory cytokine production of IL-
1α, IL-1β and IL-6. [6, 27, 29, 30, 80-82]. Interleukins act specifically as mediators 
between leukocytes. Activated leukocytes can generate ROS, which contributes to 
hypertension and atherosclerosis [83]. Many autoimmune disorders are strongly 
associated with cardiac and metabolic disorders.  
Women tend to have slightly higher serum CRP than men with the same body 
mass index (BMI) and age; however, these differences are not pronounced enough to 
warrant gender-dependent reference ranges [84, 85] . The role of gender in predisposition 
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to oxidative stress has yet to be determined. CRP is an acute phase inflammatory marker 
considered to be a reliable prognostic indicator of atherosclerosis and acute myocardial 
infarction (AMI) [61, 82, 86]. Urinary levels peak approximately 24 hours following the 
inflammatory event and are undetectable within 13 to 16 hours. As a measure of 
leukocyte infiltration, MPO is an inflammatory marker used to predict the risk of AMI in 
the absence of cardiac necrosis [54, 87]. The predictive value of this marker has not been 
fully characterized; however, it is associated with long term adverse cardiac events. E2 
has been suggested as a potential endogenous substrate for MPO in plasma [88]. 
Recognition and elaboration of the innate differences of gender physiology may result in 
better treatment adaptations for women and better outcomes [89]. 
 
2.2 Inflammation 
 
 Inflammation can be classified as either acute or chronic. Acute inflammation is 
the initial response to harmful stimuli and is achieved by mobilization of plasma and 
leukocytes, particularly granulocytes, from the blood into the injured tissues. It is 
characterized by vasodilation, increased permeability and reduced blood flow; these 
changes are induced by multiple inflammatory mediators [90]. Trauma, inflammation, or 
infection leads to the activation of the inflammatory cascade. A progression of 
biochemical events, including components of the local vasculature, the immune system, 
and various cells triggers the inflammatory response. Unlike acute inflammation, chronic 
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inflammation is mediated by cells such as monocytes and lymphocytes. Chronic 
inflammation leads to a progressive shift in the type of cells present at the site of 
inflammation and is characterized by simultaneous destruction and healing of the tissue 
from the inflammatory process [91]. 
 Tissue macrophages, monocytes, mast cells, platelets, and endothelial cells are 
able to produce a multitude of cytokines. The release of as IL-1α and IL-1β leads to 
cleavage of the nuclear factor-kB (NF-kB) inhibitor. Removal of the inhibitor allows NF-
kB to initiate mRNA production, thereby inducing production of other proinflammatory 
cytokines like IL-6. IL-1 is responsible for fever and the release of stress hormones 
(norepinephrine, vasopressin, activation of the renin-angiotensin-aldosterone system). 
Cytokines like IL-6 stimulate the release of acute-phase reactants such as CRP.  Infection 
has been shown to elicit a stronger response than trauma, which translates to a greater 
release of IL-6. Estrogen has been shown to directly inhibit IL-6 production [92]. 
 Inflammation is a highly regulated process that recruits the immune system to 
sites of infection and injury and to facilitate tissue repair processes. Prolonged 
inflammation produces local and systemic damage associated with a loss of normal 
physiological functions. Activation of proinflammatory cytokines results in 
vasodilatation, release of cytotoxic compounds like MPO, generation of ROS and 
damage to the vasculature.  Proinflammatory cytokines like IL-1α, IL-1β and IL-6 
upregulate endothelial enzyme expression which plays an important role in atherogenesis. 
Some autoimmune diseases, such as RA, SLE and Sjogren's syndrome, are characterized 
by chronic inflammation.  
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 Chronic inflammation is a crucial element in the development of multiple disease 
processes, including renal dysfunction, cardiovascular disease, autoimmune disorders, 
cancer and DM [53, 91]. Assessment of inflammatory markers like CRP, MPO and the 
interleukins can lead to improved risk stratification in disease. Estrogen and testosterone 
can affect the expression of proinflammatory markers in macrophages. Testosterone may 
reduce the expression and secretion of IL-1β, but it does not appear to affect the 
expression of IL-6 or CRP. Estrogen elicits a variable response in CRP expression [93].  
 Aldosterone causes tissue inflammation; this may result in fibrosis and 
remodeling in the heart, vasculature, and kidney [94]. Aldosterone triggers endothelial 
cell exocytosis, which is a crucial step in leukocyte mobilization [95]. During active 
inflammatory disease such as Crohn‟s disease or RA, metabolic shifts may cause in 
hypoxia in affected membranes. Activation of hypoxia-inducible factor (HIF) subsequent 
to hypoxia has been shown to upregulate production of hsp90α and VEGF [96]. VEGF 
increases endothelial permeability and is associated with microalbuminuria and 
myoglobinuria [97].  
 
2.3 Oxidative stress 
 
 Oxidative stress is determined by the balance between the rate at which oxidative 
damage in a cell, tissue, or organ is induced and the rate at which it is repaired or 
removed. Inactivation of ROS by endogenous antioxidants like superoxide dismutase and 
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glutathione peroxidase determines the rate at which damage is induced [67, 98]. Repair 
enzymes determine the rate at which damage is repaired. Most ROS come from the 
endogenous sources as by-products of normal and essential metabolic reactions.  
Lifestyle and environmental exposures also contribute to ROS. While there are many 
biomarkers of inflammation, oxidative stress is difficult to measure in vivo. Traditional 
indices of oxidative stress include markers of oxidative damage to lipids, proteins and 
DNA. Oxidative stress is also indirectly assessed by measuring markers of inflammation 
such as MPO[99]. 
 ROS include free radicals and peroxides such as hydrogen peroxide, 
hypochlorous acid and peroxynitrite. When converted by oxidoreduction reactions, 
superoxide can be transformed into more aggressive radical species capable of causing 
extensive cellular damage. Long term effects of ROS exposure can include damage to 
DNA. Oxidative stress is implicated in diseases such as atherosclerosis, Parkinson's 
disease, heart failure, myocardial infarction, Alzheimer's disease, fragile X syndrome and 
chronic fatigue syndrome. Oxidative stress is linked to certain cardiovascular diseases; 
oxidation of low density lipoprotein in the vascular endothelium is a precursor of 
atherosclerotic plaque formation. Oxidative stress plays a role in the ischemic cascade 
due to oxygen reperfusion injury following hypoxia. It is also associated with the 
detrimental effects of aging. 
 Aging induces a pro-inflammatory state characterized by increasing levels of 
inflammatory cytokines such as IL-1α, IL-1β and IL-6 [100, 101]. Aging is associated 
with a declining serum testosterone levels. Studies suggest a close relationship exists 
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between the development of a pro-inflammatory state and the decline in testosterone 
levels, two trends that are often observed in aging men. Additionally, E2 is weakly 
associated with IL-6 in older men, independent of testosterone. 
 Myoglobin is a molecular radical scavenger activated by ischemia and myolysis; 
serum and urine myoglobin concentrations increase with OS [33, 102]. Creatinine 
concentrations are associated with muscle mass. Activity of creatinine and myoglobin 
correlate to stress induced neutrophil response common in exertional and injury induced 
rhabdomyolysis [103]. Aldosterone is linked to generation of ROS and the induction of 
oxidative stress [104, 105]. Atrial natriuretic peptide (ANP) is a hormone, primarily 
produced by cardiomyocytes, which regulates blood pressure. Studies have linked ANP 
with the generation of ROS. ANP may produce either antioxidant or prooxidant effects, 
depending on experimental conditions and cell context [106]. 
 ROS generation occurs in hepatocytes and in the respiratory burst of Kupffer 
cells, triggering a proinflammatory cascade upregulating multiple interleukins. Specific 
receptors in hepatocytes stimulate the expression of antioxidant enzymes such as 
manganese superoxide dismutase and acute-phase proteins. These responses help protect 
the liver against ischemia-reperfusion injury[107]. OS plays an important role in 
pathogenesis of hepatic diseases like alcoholic liver injury. Cardiac surgery-associated 
acute kidney injury (AKI) is common and is associated with increased expression of 
NGAL [105]. Increased OS is considered a causative factor of DM, particularly diabetic 
cardiovascular and renal sequelae. Hyperglycemia is thought to induce the 
overproduction of ROS. Oxidative stress is also a factor in the pathogenesis of 
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hypertension and target organ damage, largely due to its effects on the vasculature. 
Oxidative metabolites of cocaine generate significant ROS; much of the 
pathophysiological damage associated with cocaine use stems from oxidative stress and 
electron transfer[32]. 
 
2.4 Cocaine 
 
 Cocaine, C17H21NO4, is a potent cardiac and central nervous system stimulant. It 
is fat soluble and freely crosses the blood-brain barrier. Cocaine is rapidly hydrolyzed by 
serum cholinesterase in plasma and carboxylesterases in the liver following use; the 
primary metabolites are BE and EME (Figure 2).  Lesser metabolites include 
cocaethylene (CE), norcocaine and anhydrous ecgonine methyl ester (only seen in crack 
cocaine use). Cocaine and ethanol are independently cardiotoxic; together they exhibit 
synergistic cardiotoxicity. In the presence of alcohol, a nonspecific carboxylesterase 
catalyzes ethyl transesterification of cocaine to CE. Animal studies have demonstrated 
that co-administration results in prolonged cardiac toxicity and dysrhythmias [108]. It has 
also been demonstrated that ED patients with detectable CE concentrations are more 
likely to be admitted to intensive care units than those patients testing negative for CE 
[109]. The half-lives of cocaine, CE and BE are 40 minutes, 2.5 hours and 5 to 8 hours 
respectively. This may explain why cocaine-related symptoms can continue for some 
time after cocaine is last used. Cocaine has only one biologically active metabolite, 
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norcocaine. The oxidative metabolism of cocaine to norcocaine nitroxide is postulated to 
be essential for cocaine hepatotoxicity [110].  
 Cocaine induces local vasoconstriction and an anesthetic effect by inhibiting fast 
sodium channels. Cocaine is a strong sympathomimetic that blocks catecholamine 
reuptake, effectively flooding the synaptic space with norepinephrine thereby stimulating 
the central and peripheral nervous systems [56]. The effect of cocaine is especially 
pronounced in the limbic system where it potentiates dopaminergic transmission in the 
 
 
Figure 2. Metabolites of Cocaine 
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ventral basal nuclei. The potentiation of dopamine is responsible for the pleasurable 
behavioral effects that make cocaine a popular drug of abuse. Cocaine causes moderate 
release and reuptake-blockade of serotonin and dopamine [111-113]. Cocaine-induced 
hyperpyrexia, a potentially fatal elevation in body temperature exceeding 41° C, is 
thought to be associated with dopamine receptor blockade in the temperature regulation 
region of the hypothalamus. The sodium channel blockade decreases the resting 
membrane potential and action potential amplitude while simultaneously prolonging the 
duration of the action potential. Cocaine also blocks potassium channels. In some cellular 
membranes, it may block sodium-calcium exchange.  
 Almost every organ system is affected by cocaine use. Myocardial infarction, 
arrhythmias, renal failure, hypertension, atherosclerosis, and rhabdomyolysis are all in 
the spectrum of acute and chronic cocaine toxicity [114, 115].  Cocaine is associated with 
an increased vascular risk; the brain, heart, kidney, liver and lungs are all susceptible to 
its vasculotoxicity. It can cause abrupt changes in blood pressure, embolism via infective 
endocarditis, and hemostatic and hematologic abnormalities that can result in increased 
blood viscosity and platelet aggregation. Most ED patients with cocaine-associated chest 
pain have normal cardiac profiles at the time of presentation. The negative inotropic 
effects of cocaine observed in animal models do not appear to be present in patients who 
develop chest pain after using recreational doses of cocaine [116]. 
 Cocaine is known to have specific, dose-dependent effects on brain and body 
temperatures, these effects are strongly modulated by an individual's activity state and 
environmental conditions, and change dramatically during the development of drug self-
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administration. Environmental conditions potentiate the thermal effects of cocaine which 
may result in pathological brain overheating. Hyperthermia can exaggerate the toxicity of 
cocaine; environmental conditions that impair heat loss can result in acute life-
threatening complications and chronic destructive CNS changes [117]. Deleterious 
effects of hyperthermia include activation stress response systems, decreased immune 
efficiency, increased blood viscosity, vasoconstriction, renal and hepatic insufficiency 
and rhabdomyolysis. 
 Rhabdomyolysis is a disorder in which injury to muscle results in leakage of 
myocyte intracellular contents into the plasma. Dissolution of muscle fibers and leakage 
of muscle enzymes, myoglobin, potassium, calcium, and other intracellular constituents, 
can occur. For this reason, myoglobinuria and albuminuria are common clinical markers 
of rhabdomyolysis. Serum proinflammatory and inflammatory cytokines like IL-1α, IL-
1β, MPO and CRP are similarly elevated. Cocaine has been shown to diminish IL-6 
response to proinflammatory challenges [118]. IL-6 is a multifunctional cytokine 
implicated in many age-related diseases, including postmenopausal osteoporosis and 
Alzheimer‟s disease [119]. The most likely etiology of rhabdomyolysis in patients 
presenting to the emergency department is ingestion of drugs of abuse such as cocaine 
[58]. The hemodynamic actions of cocaine contribute to renal injury. Cocaine abuse has 
been linked with acute renal failure and acid-base and/or electrolyte disorders and may 
trigger the progression of chronic renal failure to end-stage renal disease. 
 Cocaine use is associated with frontal cortex and glial injury in both frontal gray 
and white matter. Women showed equivalent responses to drug administration with the 
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exception of the limbic system; their perception of well-being was significantly increased 
[120]. These findings may have implications for differential risk for acute and chronic 
toxicity in women. Some animal studies suggest estradiol increases sensitivity of the 
brain reward system [121].Progesterone may enhance cocaine craving and relapse 
susceptibility in women [122]. Research also suggests adolescents are more sensitive than 
adults to interactions between testosterone and cocaine [123].  
 There are significant gaps in the literature that make it difficult to define the 
relationship between gender and cocaine. Social parameters have been described; males 
are more likely than females to use cocaine and males tend to use cocaine at an earlier 
age than do females. The pathophysiological gender based differences cannot be 
elaborated until study populations begin to include females. The bulk of research 
performed in recent years has focused on psychosocial and neurobiological differences 
between cocaine using females and males [124-126]. Given the stark physical contrasts 
between the genders, particularly in immune response and autoimmunity, the focus may 
need to be widened to include gender based differences in the inflammatory and 
oxidative response to cocaine use. 
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Chapter 3.0 
Materials and Methods 
 
The Agency for Community Testing Services (ACTS) Laboratories provided 
urine specimens with all information blinded apart from gender, creatinine and the results 
of the NIDA 10 drug screen. 41 specimens were donated by males, 39 specimens by 
females.  40 specimens tested negative to all substances on the NIDA 10 panel (THC, 
opiates, amphetamines, barbiturates, cocaine, ethanol, benzodiazepines, propoxyphene, 
methadone and oxycodone) and 40 specimens tested positive for cocaine metabolites 
alone. Limited demographic information was available for some of the donors; for 
example, age was available for 66 of the donors. The donors‟ ages ranged from 16 to 62; 
the mean donor age was 34 years old.  Donor weight was available for 46 of the 80 
donors. The female weights ranged from 113 to 327 lbs and the mean female donor 
weight was 162.5 lbs. The male weights ranged from 120 to 240 lbs and the mean male 
donor weight was 166.6 lbs.  
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Table 1. Summary of Assays Performed 
Analyte Method Manufacturer 
Total Protein  Colorimetric Pierce 
Creatinine Colorimetric Cayman 
Cocaine/Benzoylecgonine (BE) ELISA Immunalysis 
Aldosterone ELISA ALPCO 
C Reactive Protein (CRP) ELISA ALPCO 
Myeloperoxidase (MPO) ELISA ALPCO 
Microalbumin (MAB) ELISA ALPCO 
Myoglobin (MGB) ELISA Life Diagnostics 
Heat Shock Protein 90α (hsp90α) ELISA Assay Designs 
Vascular Endothelial Growth Factor 
(VEGF) 
ELISA Raybiotech 
Neutrophil Gelatinase Associated 
Lipocalin (NGAL) 
ELISA Quantikine 
Pro Atrial Natriuretic Peptide 
(proANP) 
ELISA ALPCO 
Interleukin 1α (IL 1α) ELISA Cayman 
Interleukin 1β (IL1β) ELISA Cayman 
Interleukin 6 ELISA Cayman 
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3.1 EMIT 
 
Enzyme Multiplied Immunoassay Technique (EMIT) is a common method for 
screening urine and blood for drugs, legal and illicit. This inexpensive technique is fast, 
relatively sensitive and specific, and has been adapted to various automated analyzers.  
The non-linear relationship between the change in absorbance and analyte/drug 
concentration in the specimen is the reason the assay is only useful for qualitative 
determinations. Results are expressed as Δ absorbance (M) units and compared with 
results for cutoff-value calibrators to indicate a positive or negative result. This 
qualitative procedure may be followed with confirmatory (quantitative) GC/MS testing as 
necessary. 
  An EMIT drug test contains antibodies that target specific drugs in the urine 
specimen. If an antibody does not become attached to the drug in the urine specimens, it 
attaches itself to the chemically tagged drug in the EMIT reagent. ACTS uses 
DRI/Microgenics (Thermo Fisher Scientific Corporation, Waltham, MA 02454) reagents 
and controls for the NIDA 10 EMIT panel. The NIDA 10 panel consists of Cocaine 
(COC), Amphetamine (AMP), Methamphetamine (M-AMP), Tetrahydrocannabinol 
(THC), Methadone (MTD), Opiates (OPI), Phencyclidine (PCP), Barbiturates (BAR), 
Benzodiazepines (BZD) and Oxycodone (OXY) in human urine.  Chemically tagged 
drugs without an attached antibody (i.e. the reagent) are transformed by a reaction that 
changes the absorbance of the test sample. Attachment of an antibody inhibits this 
reaction. The Olympus AU640e Chemistry ImmunoAnalyzer (OLYMPUS America Inc., 
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Center Valley, PA 18034-0610) used by ACTS Laboratory measures the changes in 
absorbance in the test sample; the change in absorbance is then compared to the 
absorbance of the calibrators. If the absorbance of the test sample is equal to or exceeds 
the calibrator‟s, the specimen is considered positive for the drug in question. Conversely, 
if the absorbance of the test sample is less than that of the calibrator, the specimen is 
considered negative for the drug. 
In 1988, the American Association for Clinical Chemistry (AACC) conducted a 
study of the testing accuracy of laboratories with regard to drugs of abuse. This study was 
blinded and used cutoff concentrations very close to the guidelines of the Substance 
Abuse and Mental Health Services Administration (SAMHSA).  Their overall accuracy 
rate was 97%. There were a small number of false negative results (2–4%) on samples 
with drug concentrations close to the cutoff. There were no false positive results. 
  
Components of the EMIT Assay Method (Figure 3): 
1. Drug   
2. Antibody  
3. Substrate  
4. Drug enzyme complex 
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Figure 3. EMIT Assay Components in Action 
 
3.1.1 General Procedure for EMIT Assay 
1. Mix sample containing drug with fixed quantity of enzyme bound drug, and 
antibody  
2. Add substrate  
3. Measure absorbance at 15 and 45 seconds after substrate addition  
4. Quantitate by measuring enzyme-substrate reaction (by UV - visible 
spectroscopy)  
5. Δ Absorbance from Reaction rate from Drug concentration  
6. Non linear relationship between Δ Absorbance and Concentration  
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7. Determine standard curve 
 
ACTS laboratory uses the Olympus AU640e for drugs of abuse analysis (Figure 
4). The analyzer screens urine specimens for the NIDA 10 panel of drugs. The cocaine 
test analyzes urine specimens for the presence of the primary cocaine metabolite, 
benzoylecgonine, rather than the parent compound (cocaine). As previously stated, EMIT 
does not measure the amount of the drug present; it simply detects its presence or absence 
as determined by an established cut-off level. The drug in the manufacturer‟s reagent is 
labeled with an enzyme such as glucose-6-phosphate dehydrogenase (G6PDH). The 
enzyme-ligand-antibody complex is inactive thereby allowing determination of unlabeled 
ligand. 
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Figure 4. Olympus AU640e Chemistry-Immuno Analyzer 
 
 
3.1.2 Cocaine/Benzoylecgonine  
3.1.2.1 General Principle of the Assay 
The DRI Cocaine Metabolite Assay used (DRI Cocaine Metabolite Assay #0056, 
Microgenics Corporation Fremont, CA 94538) by ACTS Laboratory is intended for the 
qualitative and semiquantitative determination of benzoylecgonine in human urine. This 
assay provides only a preliminary analytical test result.  Quantitative determination 
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requires alternative methods; gas chromatography/mass spectrometry (GC/MS) is the 
preferred confirmatory method.   
The DRI Cocaine Metabolite Assay is a homogeneous enzyme immunoassay 
using ready-to-use liquid reagents. The assay uses a specific antibody to detect 
benzoylecgonine in urine specimens. The assay is based on the competition of an enzyme 
glucose-6-phosphate dehydrogenase (G6PDH) labeled BE and any BE from the urine 
sample for a finite number of specific antibody binding sites. In the absence of BE in the 
sample, the specific antibody binds to the G6PDH labeled BE and the enzyme activity is 
inhibited. This means there is a direct relationship between the BE concentration in the 
urine and the enzyme activity. The enzyme G6PDH activity is determined by measuring 
its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH 
spectrophotometrically at 340nm using the lab‟s Olympus AU640e Chemistry-Immuno 
Analyzer. 
 
3.1.2.2 Specificity 
Benzoylecgonine, cocaine and other compounds that are concurrently present in 
the urine were tested for cross- reactivity in the assay. Cocaine and EME are the only 
compounds that demonstrated crossreactivity. Urine specimens arrive in sterile containers 
from a number of remote collection sites, including jails, hospitals and medical offices. 
Possible adulteration of urine specimens is an important consideration for drug testing 
facilities. Accordingly, samples undergo several tests to determine the likelihood of 
adulteration. Color and odor are assessed for evidence of adulteration, either by dilution 
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or the addition of an oxidant such as bleach. The tests used to check for adulteration 
include creatinine concentration, pH and specific gravity. Urine specimens with values 
outside normal reference ranges are discarded.   
The reference ranges for: 
 Urine creatinine is 25-350 mg/dL 
 Urine pH is 5.0 to 6.5 
 Urine specific gravity is 1.003 to 1.030 
 
Dilution of the specimen may result in abnormal lows for one or more of the 
markers. In some instances the specimens are highly concentrated and dilution may make 
creatinine levels normal. Substitution with a liquid other than urine will be revealed by 
the absence of creatinine. Commercial masking agents may include components such as 
glutaraldehyde to interfere with the drug screen; for this reason, nitrites levels are 
occasionally used to establish the legitimacy of a specimen. This is not foolproof as 
bacterial infection and contamination may increase urine nitrite levels.  
 
3.1.3 Creatinine 
Creatinine is routinely included in urinary analysis as a control for dilute or 
adulterated specimens. It is a metabolic by-product of creatine degradation in muscle 
tissue. Most methods for determining the creatinine concentration of a specimen, in urine 
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or serum, rely on the Jaffe reaction in which creatinine reacts with alkaline picrate to 
form a red-yellow solution that is then measured photometrically (Figure 5).  
           
    NaOH 
Creatinine + Picric Acid     Janovski Complex 
Figure 5. Modified Jaffe Reaction 
 
Since urine contains other substances which can react with picrate, the Olympus 
uses reagents from Microgenics for a modified version of the Jaffe reaction with 
improved specificity. The color intensity of the creatinine-picric acid complex is directly 
proportional to the concentration of creatinine in the urine specimen and is measured 
spectrophotometrically at 505 nm.  Each laboratory establishes its own reference range 
for creatinine levels but they average from 25 to 300 mg/dL. When the value obtained 
exceeds 300 mg/dL, the specimen should be diluted with physiological saline and re-
assayed. The established cutoff value for creatinine is 20 mg/dL and the assay is said to 
be linear to 400 mg/dL. 
 
3.1.4 Specific Gravity 
Specific gravity simply refers to the dissolved solutes present in urine as 
compared to the value set by convention, for pure water (1.000). Values obtained for 
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specific gravity are affected by the number, size and weight of molecules in urine. For 
this reason, it is considered an approximation of solute concentration. The urine specific 
gravity assay relies upon the use of a linear relationship between urinary chloride ion 
concentration and measured specific gravity. Determination of the chloride ion is 
colorimetric; in an aqueous medium, ferric perchlorate and chloride ion form a ferrous 
chloride complex that has an absorbance maximum of 340 nm (Figure 6). Absorbance at 
340 nm is directly proportional to concentration of chloride ion in the specimen. Urine 
specific gravity is extrapolated from this value. 
 
Cl
- 
+ Fe 
3+ 
  FeCl2+ 
Figure 6. Urine Specific Gravity Reaction Equation  
 
3.1.5 Ethanol 
The ethanol assay is based on the high specificity of alcohol dehydrogenase 
(ADH) for ethyl alcohol. In the presence of ADH and nicotinamide adenine dinucleotide 
(NAD), ethanol is readily oxidized to acetaldehyde and NADH (Figure 7).  The 
enzymatic reaction is monitored spectrophotometrically at 340nm. The ethanol in the 
sample is in direct proportion to the rate of change of absorbance at 340 nm.  
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Figure 7. Oxidation of Ethanol to Acetaldehyde 
 
 
3.2 Colorimetric Analysis 
Colorimetry relies on colored solutions absorbing light of a particular wavelength; 
however the technique can also be used to analyze colorless substances if they react with 
a dye. The TECAN M200 Infinite Microplate Reader (TECAN US Inc., Durham NC 
27703) can be used for simple colorimetric analyses such as the creatinine assay and total 
protein assessment. The absorbance of the urine specimens is determined by comparing 
them to a calibration curve generated from known standards. 
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3.2.1 Total Protein  
3.2.1.1 General Principle of Assay 
The Coomassie Protein Assay kit used (Coomassie Protein Assay Kit #23200, 
Pierce Biotechnology, Rockford, IL 61105) is a typical colorimetric assay. The Pierce 
Coomassie Protein reagent is a modification of the Bradford Coomassie Dye-protein 
binding colorimetric method of protein quantitation. When Coomassie dye binds to 
protein in an acidic medium, the color in the wells changes from brown to blue as the 
absorbance maximum shifts. 
A 5 μl aliquot of standard, control urine or cocaine positive (as previously 
determined by EMIT) urine specimen is incubated with a 250 μl of Coomassie Reagent in 
micro-plate wells for 10 minutes.  The plate is read at 595 nm to obtain the absorbance. 5 
μl of acid is then added to the wells. The absorbance is directly proportional to the 
concentration of protein in the sample. A set of standards is used to plot a standard curve 
from which the amount of total protein in samples and controls can be directly read. 
 
3.2.1.2 Assay Procedural Details 
Kit Contents: 
 1. Coomassie Protein Assay Reagent ready to use 
 2. Albumin Standard Ampules 2mg/ml requires serial dilution 
 38 
 
Phosphate Buffered Saline (PBS) is the diluent chosen for the assay. PBS is a commonly 
used isotonic buffer solution in biological research. The osmolarity and ion 
concentrations of the solution usually match those of the human body fluids. The 1x PBS 
stock solution used for the Total Protein Assay was prepared by dissolving 8.00 g of 
NaCl, 0.20 g of KCl, 1.44 g of Na2HPO4 and 0.24 g of KH2PO4 in 800 ml of Barnstead 
Nanopure Water. If necessary, the pH can be calibrated to 7.4 with the addition of HCl or 
NaOH. The final volume is adjusted to 1 liter with additional Barnstead Nanopure Water. 
 
The albumin standards were prepared as described in the table below (Table 2): 
Table 2. Concentration of Albumin Standards 
Tube Volume of Diluent              
(μl) 
Volume and Source of BSA                                            
(μl) 
Final
Concentration 
(μl /ml protein) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of tube B 750 
E 325 325 of tube C 500 
F 325 325 of tube E 250 
G 325 325 of tube F 125 
H 400 100 of tube G 25 
I 400 0 0 (blank) 
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All reagents must reach room temperature before use.   Mix the Coomassie 
Reagent immediately prior to use by gently inverting the bottle several times. Calibrators, 
controls and specimen samples should be assayed in duplicate.  Once the procedure has 
been started, all steps should be completed without interruption. 
5 μl of each standard, control urine and cocaine positive urine were pipetted into 
correspondingly labeled wells in duplicate.  Next, 250 μl of the Coomassie Reagent was 
pipetted into each well.  The plate was incubated on a plate shaker (approximately 200 
rpm) for 10 minutes at room temperature.  The plate was read at 595 nm to calculate the 
absorbance. A standard curve was produced and the concentration of protein in each of 
the specimens was determined from the blank- adjusted absorbance. 
 
3.2.1.3 Interfering Substances 
Most ionic and nonionic detergents 
 
3.2.2 Creatinine  
3.2.2.1 General Principle of Assay 
The Creatinine kit used (Creatinine Assay Kit #500701, Cayman Chemical 
Company, Ann Arbor, MI 48108) is a typical colorimetric assay. It is not appropriate for 
diagnostic use. It relies on the Jaffe‟ reaction; in Jaffe‟, a yellow/orange color is formed 
when the metabolite is exposed to alkaline picrate. The color derived from creatinine is 
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destroyed at acidic pH. The difference in the color before and after acidification is 
measured at 500 nm and is proportional to the creatinine concentration in the urine 
specimen.  
A 15 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is incubated with a 150 μl of Alkaline 
Picrate Solution in micro-plate wells for 10 minutes.  The plate is read at 500 nm; the 
value obtained is the Initial Absorbance. 5 μl of acid is then added to the wells. After 
incubating for 20 minutes, the Final Absorbance is obtained by reading the plate at 500 
nm. The difference between the initial and final absorbance is directly proportional to the 
concentration of creatinine in the sample. A set of standards is used to plot a standard 
curve from which the amount of creatinine in samples and controls can be directly read. 
The dynamic range of the Cayman Creatinine assay is 0 – 15 mg/dl.  
 
3.2.2.2 Assay Procedural Details 
Kit Contents: 
 1. Creatinine Standard requires dilution 
 2. Creatinine Color Reagent (1.2% picric acid) ready to use 
 3. Creatinine Sodium Hydroxide (0.1M NaOH) ready to use 
 4. Creatinine Acid Solution ready to use 
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 5. Creatinine Sodium Borate ready to use 
 6. Creatinine Surfactant ready to use 
   
To prepare Alkaline Picrate Solution sufficient for a 96 well plate, mix together 2 
ml sodium borate, 6 ml surfactant, 10 ml color reagent and 3.6 ml NaOH. This resultant 
solution is stable for one week stored in the dark at room temperature. 
Urine specimens were diluted 1:20 with Barnstead Nanopure water prior to use. 
The creatinine standards were prepared as described in Table 3: 
Table 3. Concentration of Creatinine Standards 
Tube Creatinine Standard 
(μl) 
Nanopure Water 
(μl) 
Final Concentration 
(mg/dl creatinine) 
A 0 500 0 
B 50 450 2 
C 100 400 4 
D 150 350 6 
E 200 300 8 
F 250 250 10 
G 300 200 12 
H 375 125 15 
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All reagents must reach room temperature before use.  Calibrators, controls and 
specimen samples should be assayed in duplicate.  Once the procedure has been started, 
all steps should be completed without interruption. 
15 μl of each standard, diluted control urine and diluted cocaine positive urine 
were pipetted into correspondingly labeled wells in duplicate.  Next, 150 μl of the 
alkaline picrate solution was pipetted into each well to initiate the reaction.  The plate 
was incubated on a plate shaker (approximately 200 rpm) for 10 minutes at room 
temperature.  The plate was read at 500 nm to calculate the initial absorbance. 5 μl of acid 
solution was added to all wells and the plate was incubated for 20 minutes on a plate 
shaker at room temperature. The final absorbance was calculated by reading the plate at 
500 nm. A standard curve was produced and the concentration of creatinine in each of the 
specimens was determined from the adjusted absorbance. 
 
3.3 ELISA 
 
Immunoassays are biochemical tests that measure the level of a substance in a 
biological liquid, in our case urine. The assay utilizes the specific binding relationship of 
antibody and antigen. Monoclonal antibodies are often used because they typically bind a 
single site of a particular molecule; this property enhances specificity and accuracy. 
Polyclonal antibodies have also been successfully applied for various immunoassays. 
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Assay success depends on antibody affinity for the antigen. It is possible to measure both 
the presence of antigen and antibodies.  
Enzyme-linked Immunosorbent Assay (ELISA) uses antibodies (or antigens) 
coupled with an enzyme to produce an antibody specific assay with the sensitivity of 
simple enzyme assays. This allows an ELISA to provide a useful measurement of antigen 
or antibody concentration. ELISA plates consist of 96 or 480 polyvinyl chloride 
microwells containing enzymes, antigens or antibodies immobilized on a solid phase and 
the substance. Depending on the type of ELISA, an antibody capable of detecting an 
antigen or an antigen that will elicit the response of a particular antibody is allowed to 
bind to the immobilized protein.  
There are 5 types of ELISA: direct, indirect, sandwich, competitive and multiplex: 
1. Direct ELISA: This method directly labels the antibody. The target antigen is 
applied to the microwells of an ELISA plate; bound antigen may be quantitated 
using colorimetric, chemiluminescent or fluorescent measurement. This method 
provides relatively quick results with limited cross reactivity. There is little 
opportunity for signal amplification with this method. 
2. Indirect ELISA: This two step method uses a second antibody for detection. 
The primary antibody is incubated with the antigen; the specimens in the wells 
then incubate with a second labeled antibody capable of recognizing the primary 
antibody. This method allows for considerable signal amplification. 
 44 
 
3. Sandwich ELISA: This method measures the amount of antigen ‟sandwiched‟ 
between two layers of antibodies. The sandwich ELISA requires the antigens to 
be measured contain two or more antigenic sites capable of binding the capture 
and detection antibodies; therefore, these assays are restricted to the quantitation 
of multivalent antigens such as proteins or polysaccharides. Sandwich ELISAs are 
excellent for quantitating antigens when the concentration of antigens is low or 
the concentration of contaminating protein is high.  
Briefly, the capture antibody is purified and bound to a solid phase (usually 
attached to the bottom of a plate well). Specimens thought to contain the antigen 
of interest are added to the microwells and allowed to complex with the capture 
antibody. The plates are washed to remove unbound products and the labeled 
detection antibody is allowed to bind to the antigen. This completes the 
“sandwich”. The assay is quantitated using a colorimetric substrate to measure the 
amount of detection antibody bound to the matrix.  
4. Competitive ELISA: This method requires one reagent be conjugated to a 
detection enzyme (horseradish peroxidase is one of the most commonly used). 
This detection enzyme may be linked to the antigen or the primary antibody. The 
microwells of the assay plate are coated with a purified unlabeled primary 
antibody. Following this, the plate is incubated with unlabeled standards and 
unknowns. The reaction is allowed to proceed to equilibrium; labeled conjugate 
antigen is then added to the microwells. The conjugate will bind to the available 
binding sites on the primary antibody. The plate is then developed with substrate 
and color change is measured. In a competitive ELISA, there is an inverse 
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relationship between the signal obtained and the concentration of the analyte in 
the sample i.e. the more unlabeled antigens in the sample or standard, the lower 
the amount of conjugated antigen bound.  
5. Multiplex ELISA: This assay allows simultaneous detection of multiple 
analytes arrayed in a single well. Detection method can be direct or indirect, 
sandwich or competitive, labeling or non-labeling, depending upon antibody array 
technologies. 
 
There are further assay variations depending upon the labeling and signal 
detection methodology. The basic approach stays the same: fixation of either antigen or 
antibody and detection of the antibody-antigen complex. The general steps in 
direct/competitive ELISAs can be seen in Figure 8. 
 
 
Step 1: The antibody is attached to the walls of the microtiter plate. 
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Step 2: Urine is added to the well to test for the presence of the antigen  
 
Step 3: If the antigen is present in the urine, it will bind to the antibodies attached to the 
microtiter walls. 
 
Step 4: The plates are rinsed to remove test fluid and unbound antigen. 
 
Step 5: A solution of modified antibodies is added. These antibodies carry a reporter 
enzyme designed to elicit a color change when the antigen-antibody complex forms. 
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Step 6: The sample is rinsed again to remove unbound antibodies. If the antigen is 
present, a complex consisting of antigen, plate-bound antibody and enzyme-conjugated 
antibody forms. 
 
Step 7: The substrate of the enzyme is added. A color change indicates the presence of 
the enzyme-labeled antibody and the antigen. 
Figure 8. Common Steps in Direct/Competitive ELISA Assay  
ELISAs were performed using a TECAN M200 Infinite Microplate Reader 
(TECAN US Inc., Durham NC 27703). The TECAN M200 (Figure 9) is an automated 
microplate reader is capable of UV & VIS Absorbance (ABS), Fluorescence (FL) 
Intensity Top with Time-Resolved Fluorescence, Fluorescence Resonance Energy 
Transfer, Fluorescence Intensity Bottom, Spectrally-Enhanced PMT, Photon-counting 
Luminescence, Temperature Incubation and Cuvette Port Module, Single and Dual 
Injectors. The M200 can measure wavelength range of in tunable 1nm increments, 
Injector Module for fast kinetics in FL, Abs or Luminescent modes with one or two 
injector(s). Available features include heated incubation to 420C, linear and orbital 
shaking. The M200 accommodates 6, 12, 24, 48, 96 and 384-well microplate formats. It 
is packaged with i-Control and Magellan software for instrument measurement control, 
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spectral scanning, plate definition creation and raw data acquisition saved in a MS-Excel 
format. 
 
Figure 9. TECAN M200 Infinite Microplate Reader 
 
A monochromator is an optical instrument that enables any wavelength to be 
selected from a defined optical spectrum. It operates like a tunable optical filter, allowing 
both the wavelength and bandwidth to be adjusted. A monochromator consists of an 
entrance slit, a dispersive element and an exit slit. The dispersive element diffracts the 
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light into the optical spectrum and projects it onto the exit slit. The dispersive element 
may be a glass prism or an optical grating. The infinite® M200 is designed with optical 
gratings. Rotation of the optical grating moves the spectrum across the exit slit so that 
only a small part of the spectrum (band pass) passes through the exit slit. This means that 
when the monochromator entrance slit is illuminated with white light, only light with a 
specific wavelength (monochromatic light) passes through the exit slit. The wavelength 
of this light is set by the rotation angle of the optical grating and the bandwidth is set by 
the width of the exit slit. The bandwidth can be defined as full width at half maximum 
(FWHM). 
Monochromators block undesired wavelengths. This means when the 
monochromator is set for light with a wavelength of 500 nm and the detector detects a 
signal of 10,000 counts, light with different wavelengths is effectively dampened. Double 
monochromators setups permit a higher level of blocking; two monochromators are 
connected in series so that the exit slit of the first monochromator acts as the entrance slit 
of the second monochromator. This arrangement boosts the blocking count by a factor of 
10
3
. In the infinite M200, a double monochromator is installed on both the excitation and 
detection side. This opens the opportunity for easy selection of excitation and 
fluorescence wavelengths with no limitations by cut off filters. 
The i-control and Magellan software packaged with the TECAN M200 make 
operation of the microplate reader relatively simple (Figure 10). The user is able to select  
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Figure 10. I-Control/Magellan User Interface 
from a variety of common microplate conformations. The injectors can be programmed 
to automate reagent injection at specific stages of the assay, reducing operator error such 
as faulty pipetting. The operator can set the absorbance wavelengths, measured and 
reference, and determine the read pattern in the same panel. The Magellan software is a 
wizard based interface; users can start a measurement wizard, evaluate results wizard, 
create and edit sample ID lists wizard, and create and edit methods (analysis protocols) 
wizard. Users can edit plate geometry to design the assay that suits their research. Results 
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can be displayed as absorbance or concentration (calculated from the standard 
curve/calibrator data) in each microwell (Figure 11).  Results can also be displayed as 
averages when specimens are assayed in duplicate. 
 
 
Figure 11. Typical Magellan Microwell Absorbance Results 
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Figure 12.  TECAN Columbus Strip Washer 
Use of an automated plate washer enhances assay accuracy by ensuring complete 
well aspiration and washing. The laboratory used the Columbus Strip Washer (Figure 
12). It is a fully automated microplate strip washer for 96- and 384-well plates. Its 
features include manifolds of 8, 12 or 16 channels, crosswise aspiration, overflow and 
bottom washing. Assay protocols can either be programmed on board or via PC interface 
using the WinWash software. Thirty distinct methods can be programmed and stored 
simplified operation. A liquid sensor system monitors the liquid level of waste, wash 
buffer and rinse solution. Rinsing is fully automated, ensuring easy maintenance and 
operation. 
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3.3.1 Cocaine/Benzoylecgonine  
3.3.1.1 General Principle of Assay 
The principle of the Cocaine/Benzoylecgonine ELISA Kit used 
(Cocaine/Benzoylecgonine Direct ELISA Kit #212-0480, Immunalysis Corporation, 
Pomona, California  91767) is based upon the competitive binding to antibody of enzyme 
labeled antigen and unlabeled antigen, in proportion to their concentration in the reaction 
mixture. Unmetabolized cocaine urine concentration is far lower than that of its major 
metabolite BE. Cocaine is undetectable (at a 50 ng/ml cut-off) 12 hours after 
administration in comparison with BE which persists for up to 48 hours after use. ). It has 
been suggested that a BE/cocaine ratio of less than 100 is indicative of use within the past 
10 hours. Results are expressed in BE equivalents per ml. 
A 20 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is incubated with a 100 μl dilution of 
horseradish peroxidase labeled BE derivative in micro-plate wells, coated with fixed 
amounts of oriented high affinity purified polyclonal antibody. The wells are washed 6 
times thoroughly and a chromogenic substrate added. The color produced is stopped 
using a dilute acid stop solution and the wells read at 450 nm. The intensity of the color 
developed is inversely proportional to the concentration of drug in the sample. The 
technique is sensitive to 1 ng/ml. 
The precision of the Immunalysis Cocaine/Benzoylecgonine Direct ELISA Kit 
has been verified by assessment of the mean, standard deviation (SD) and coefficients of 
variation (CV) in data resulting from repetitive assays. Assay sensitivity based on the 
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minimum BE concentration required to produce a four standard deviation from assay Ao 
is 1 ng/ml. 
 
3.3.1.2 Assay Procedural Details 
Kit contents: 
1. 96 well micro-plate coated with polyclonal anti-benzoylecgonine and 
polyclonal anti-cocaine 
2. Cocaine/Benzoylecgonine-Enzyme Conjugate solution 
3. Positive Reference Standard containing 50 ng/ml of BE dissolved in a synthetic 
urine  
4. Negative Standard 
5. TMB chromogenic substrate 
6. Stop Reagent containing 1 N hydrochloric acid  
 
 All reagents were brought to room temperature prior to use.  Positive reference 
standards of 0, 10, 25 and 50 ng/ml were prepared. Dilution of the urine specimens with 
PBS pH 7.0 was unnecessary.  20 μl of appropriately diluted calibrators and standards 
were pipetted to each well in duplicate. 20 μl of the diluted specimens were pipetted in 
duplicate to the appropriate wells.  Next, 100 μl of the Enzyme Conjugate was added to 
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each well. After tapping the sides of the plate holder to ensure proper mixing, the plate 
was incubated in the dark for 60 minutes at room temperature. 
The microplate wells were washed 6 times with 350 μl Barnstead Nanopure 
water. Following incubation, the microplate was inverted and slapped vigorously on 
absorbent paper to ensure all residual moisture was removed. This step was critical to 
remove residual enzyme conjugate. Next, 100 μl of Substrate reagent was added to each 
well and the sides of plate holder tapped to ensure proper mixing. The plate was 
incubated in the dark for 30 minutes at room temperature. 100 μl of Stop Solution was 
added to each well, changing the blue color to yellow. Absorbance was measured at a 
dual wavelength of 450 nm and 650 nm. A standard curve was produced and the 
concentration of BE in each of the specimens was determined. 
 
3.3.1.3 Cross-Reactivity 
Aliquots of a human urine matrix were spiked with the following compounds at a 
concentration of 5000 ng/ml. None of these compounds gave values in the assay that 
were equal to or greater than the assay sensitivity level (<1 ng/ml). 
Acetaminophen, Acetylsalicylic acid, Amphetamine, Aminopyrine, Ampicillin, 
Amobarbital, Ascorbic acid, Atropine, Barbital, Butabarbital, Caffeine, Carbamazepine, 
Codeine, Chloroquine, Chloropromazine, Carbromal ,Desipramine, Dextromethorphan, 
Dextropropoxyphene, 5,5- Diphenylhydantoin, 10-11-Dihydrocarbamazepine, Diazepam, 
Ethosuximide, Estriol, Estrone, Estradiol, Ethotoin, Glutethimide, Hexobarbital, 
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Ibuprofen, Imipramine, Lidocaine, LSD, MDA, MDMA, Methadone, Methadone - 
primary metabolite, Methaqualone, Methamphetamine, Metharbital, Mephenytoin, α-
Methyl-propylsuccinimide, Mephobarbital, Methyl PEMA, Methsuximide , 4-
Methylprimidone, Morphine, Meperidine, Niacinamide, Norethindrone, N-
Normethsuximide, Phenobarbital, Phensuximide, PEMA, Primidone, Phencyclidine, 
Pentobarbital, Phenothiazine, Phenylpropanolamine, Procaine, Quinine, Secobarbital, 
Tetracycline, Tetrahydrozoline, THCCOOH 
 
3.3.2 Aldosterone 
3.3.2.1 General Principle of Assay 
The Aldosterone EIA kit used (Aldosterone Direct EIA Kit #11-ALDHU-E01, 
ALPCO Diagnostics, Salem, NH 03079) follows the typical competitive binding 
scenario. Unlabeled antigen (present in standards, control and samples) and an enzyme-
labeled antigen (conjugate) compete for a limited number of antibody binding sites on the 
microplate. The kit can be used with urine specimens with significant pretreatment 
(hydrolysis, neutralization and dilution). Approximately 1 ml of urine is required per 
duplicate determination. 
A 50 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is incubated with a 100 μl dilution of 
horseradish peroxidase labeled aldosterone derivative in micro-plate wells, coated with 
fixed amounts of oriented high affinity purified polyclonal antibody. The wells are 
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washed 3 times thoroughly and a chromogenic substrate added. The color produced is 
stopped using a dilute acid stop solution and the wells read at 450 nm. The intensity of 
the color formed is inversely proportional to the concentration of aldosterone in the 
sample. A set of standards is used to plot a standard curve from which the amount of 
aldosterone in samples and controls can be directly read. 
The lower detection limit is calculated from the standard curve by determining the 
resulting concentration of the mean OD of Calibrator A (based on 10 replicate analyses) 
minus 2 SD. Therefore, the sensitivity of the Direct Aldosterone ELISA kit is 15pg/ml. 
3.3.2.2 Assay Procedural Details 
Kit Contents: 
1. Rabbit Anti-Aldosterone Antibody Coated Microwell Plate 
2. Aldosterone-Biotin: Avidin-Horse Radish Peroxidase (HRP) Conjugate  
3. Aldosterone Calibrators  
4. Control - Ready To Use.  
5. Wash Buffer Concentrate    
6. Assay Buffer   
7. TMB Substrate    
8. Stopping Solution       
 
 58 
 
3.3.2.3 Urine Pretreatment 
1 ml of each urine sample was pipetted into an appropriately labeled glass or 
polypropylene tube. 0.1 ml of 3.2 N HCl was added to every tube. 3.2 N HCl can be 
made by adding 1 ml of concentrated HCl (12N) to 2.75 ml distilled water. Tubes were 
then capped securely and heat for 1 hour at 60oC in the dark.    Urine specimens were 
neutralized by adding 0.1 ml of 3.2 N NaOH to every tube. 3.2 N NaOH can be made by 
dissolving 1.28 grams of NaOH pellets into 10 ml distilled water. Tubes were then mixed 
gently and thoroughly.   The final step in pretreatment requires the dilution of samples 
1:50 with calibrator A.   
  All reagents must reach room temperature before use.  Positive reference 
standards of 0, 20, 80, 300, 800 and 2000 pg/ml are provided ready to use. Calibrators, 
controls and specimen samples should be assayed in duplicate.  Once the procedure has 
been started, all steps should be completed without interruption. The conjugate was 
prepared by diluting the aldosterone-biotin: avidin-HRP concentrate 1:50 in assay buffer 
(240 μl of HRP in 12ml of assay buffer).  The wash buffer was prepared by diluting the 
wash buffer concentrate 1:10 with Barnstead Nanopure water (50 ml of the wash buffer 
concentrate in 450 ml of water).   
50 μl of each calibrator, treated control urine and treated cocaine positive urine 
were pipetted into correspondingly labeled wells in duplicate.  Next, 100 μl of the 
conjugate working solution was pipetted into each well.  The plate was incubated on a 
plate shaker (approximately 200 rpm) for 1 hour at room temperature.  The wells were 
washed 3 times with 300 μl of diluted wash buffer per well.  The plate was tapped firmly 
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against absorbent paper to ensure complete drying.  150 μl of TMB substrate was pipetted 
into each well at timed intervals and the plate was incubated on a plate shaker for 10-15 
minutes at room temperature.  An alternate endpoint is to allow calibrator A to attain a 
dark blue color for desired OD.  50 μl of stopping solution was added to each well at the 
same timed intervals as in the TMB step.  Finally, the plate was read at 450nm within 20 
minutes after addition of the stopping solution.   A standard curve was produced and the 
concentration of aldosterone in each of the specimens was determined. 
3.3.2.4 Cross-Reactivity 
The following compounds cross-reacted at less than 0.001%: Androsterone, 
Cortisone, 11-Deoxycortisol, 21-Deoxycortisol, Dihydrotestosterone, Estradiol, Estriol, 
Estrone and Testosterone. 
 
3.3.3 C Reactive Protein  
3.3.3.1 General Principle of the Assay 
The high sensitivity C Reactive Protein EIA kit used (high sensitivity C Reactive 
Protein  #30-9710s, ALPCO Diagnostics, Salem, NH 03079) was a sandwich enzyme 
immunoassay intended for the quantitative determination of C  reactive protein in plasma, 
serum, stool and urine. The combination of two specific antibodies in the CRP ELISA 
significantly reduces the possibility of false negatives. It is for in vitro diagnostic use 
only. The wells of the microplate are coated with polyclonal antibodies directed against C 
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reactive protein. The kit may be used with plasma, serum, stool and urine with little 
pretreatment.  
A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is added to the appropriate wells in 
duplicate and incubated for an hour. The plate is then washed 5 times to remove all 
unbound substances. 100 μl of the diluted peroxidase-labeled CRP conjugate antibody is 
added and the plate is incubated for another hour. The plate is washed 5 times and a 
chromogenic substrate is added. After allowing the plate to incubate for 20 minutes, an 
acidic stopping solution is then added. The intensity of the color that forms is directly 
proportional to the concentration of CRP in the sample. A dose response curve of the 
absorbance (at 450 nm) unit vs. concentration is generated. CRP, present in the patient 
samples, is determined directly from this calibration curve. The assay is sensitive to 0.124 
ng/ml. 
 
3.3.3.2 Assay Procedural Details 
Kit Contents:   
1.  Microplate with precoated strips  
2.   Wash buffer concentrate  
3.   Antibody, (rabbit-anti-CRP, Peroxidase-labeled)  
4.   Calibrators, ready to use, (0; 1.9; 5.6; 16.7; 50; 150 ng/ml) 
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5.   Control 
6.   Sample buffer 
7.   TMB chromogenic substrate  
8.    Stop solution containing sulfuric acid 
 
All reagents and samples should be at room temperature (18-26 °C) prior to use. 
Positive reference standards of 0, 1.9, 5.6, 16.7, 50 and 150 ng/ml are provided ready to 
use.  Urine specimens must be diluted 1:5 with sample dilution buffer. The wash buffer 
concentrate was diluted 1:10 with Barnstead Nanopure Water before use (100 ml 
concentrated wash buffer + 900 ml Nanopure Water).  Crystals formed in the wash buffer 
concentrate (a common occurrence due to high salt concentration in the stock solutions); 
this necessitated soaking the concentrate in a 37°C using a water bath before dilution. 
The conjugate required a 1: 100 dilution in wash buffer (100 μl concentrated conjugate + 
9900 μl wash buffer).  
Calibrators, controls and specimen samples should be assayed in duplicate.  The 
plate was washed 5 times prior to use by dispensing 250 μl of diluted wash buffer into 
each well.  100 μl of appropriately diluted calibrators, standards and specimens were 
pipetted to each well in duplicate. After incubating at room temperature on a plate shaker 
for an hour, the contents of the wells were discarded and the plate was washed 5 times 
with 250 μl diluted wash buffer. Next, 100 μl of the Enzyme Conjugate was added to 
each well. After tapping the sides of the plate holder to ensure proper mixing, the plate 
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was covered tightly and incubated on a plate shaker for 60 minutes at room temperature. 
The microplate wells were washed 5 times with 250 μl diluted wash buffer. Next, 100 μl 
of Substrate reagent was added to each well and the sides of plate holder tapped to ensure 
proper mixing. The plate was incubated in the dark for 15 minutes at room temperature. 
50 μl of Stop Solution was added to each well and the absorption was read immediately 
at 450 nm against 620 nm as a reference. 
 
3.3.3.3 Cross Reactivity 
Alpha-1-Antitrypsin 0 % 
Lysozyme 0 % 
Albumin 0 % 
Other acute phase proteins 0 % 
No cross reactivity with CRP in mouse serum was observed. 
 
3.3.4 Myeloperoxidase  
3.3.4.1 General Principle of the Assay 
The Myeloperoxidase EIA kit used (Myeloperoxidase  #30-6630, ALPCO 
Diagnostics, Salem, NH 03079)is a sandwich enzyme immunoassay intended for the 
quantitative determination of MPO in plasma, serum, stool and urine. The combination of 
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two specific antibodies in the MPO ELISA significantly reduces the possibility of false 
negatives. It is for in vitro diagnostic use only. The wells of the microplate are coated 
with polyclonal antibodies directed against MPO. The kit may be used with urine with 
little pretreatment aside from dilution.  
This ELISA is suitable for the quantitative determination of MPO in urine and 
stool. In the first incubation step, the MPO in the samples is bound to available antibodies 
against MPO immobilized on the surface of the microwells. To remove all unbound 
substances, a washing step is carried out. In a second incubation step, a peroxidase-
labeled antibody against MPO is added. After another washing step to remove all 
unbound substances, the solid phase is incubated with the chromogenic substrate TMB. 
An acidic stop solution is then added to stop the reaction. The intensity of the yellow 
color is directly proportional to the concentration of MPO in the sample. A dose response 
curve of the absorbance unit vs. concentration is generated, using results obtained from 
the calibrators. MPO, present in the samples, is determined directly from this curve. 
3.3.4.2 Assay Procedural Details 
Kit Contents:   
1.  Microplate with precoated strips  
2.   Wash buffer concentrate  
3.   Detection Antibody (biotinylated) 
4.   Standards, lyophilized 
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5.   Control, lyophilized 
6.  Conjugate, (streptavidin peroxidase labeled) 
7.   Sample Dilution buffer 
8.   TMB chromogenic substrate  
9.    Stop solution containing sulfuric acid 
 
All reagents and samples should be at room temperature (18-26 °C) prior to use. 
The Control and Positive reference standards of 0, 3.6, 11, 33 and 100 ng/ml are 
lyophilized and must be reconstituted in 500 μl Barnstead Nanopure Water prior to use.  
Urine specimens must be diluted 1:10 with sample dilution buffer. The wash buffer 
concentrate was diluted 1:10 with Barnstead Nanopure Water before use (100 ml 
concentrated wash buffer + 900 ml Nanopure Water).  Crystals formed in the wash buffer 
concentrate (a common occurrence due to high salt concentration in the stock solutions); 
this necessitated soaking the concentrate in a 37°C using a water bath before dilution. 
The conjugate required a 1: 101 dilution in wash buffer (100 μl concentrated conjugate + 
10 ml wash buffer).  The Antibody required a 1: 101 dilution in wash buffer (100 μl 
concentrated antibody + 10 ml wash buffer). 
Calibrators, controls and specimen samples should be assayed in duplicate.  The 
plate was washed 5 times prior to use by dispensing 250 μl of diluted wash buffer into 
each well.  100 μl of appropriately diluted calibrators, standards and specimens were 
 65 
 
pipetted to each well in duplicate. After incubating at room temperature on a plate shaker 
for an hour, the contents of the wells were discarded and the plate was washed 5 times 
with 250 μl diluted wash buffer. Next, 100 μl of the diluted antibody was added to each 
well. After tapping the sides of the plate holder to ensure proper mixing, the plate was 
covered tightly and incubated on a plate shaker for 60 minutes at room temperature. The 
microplate wells were washed 5 times with 250 μl diluted wash buffer. Next, 100 μl of 
the diluted conjugate was added to each well. . After tapping the sides of the plate holder 
to ensure proper mixing, the plate was covered tightly and incubated on a plate shaker for 
60 minutes at room temperature. The microplate wells were washed 5 times with 250 μl 
diluted wash buffer. Next, 100 μl of Substrate reagent was added to each well and the 
sides of plate holder tapped to ensure proper mixing. The plate was incubated in the dark 
for 15 minutes at room temperature. 50 μl of Stop Solution was added to each well and 
the absorption was read immediately at 450 nm against 620 nm as a reference. 
 
3.3.4.3 Cross Reactivity 
No cross reactivity to other plasma proteins in stool. 
Alpha-1-Antitrypsin, Albumin, CRP, Lysozyme, sIgA, PMN-Elastase, Calprotectin 
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3.3.5 Microalbumin  
3.3.5.1 General Principle of the Assay 
The Microalbumin EIA kit used (Microalbumin  # 24-MABHU-E01, ALPCO 
Diagnostics, Salem, NH 03079)is a competitive  enzyme immunoassay intended for the 
quantitative determination of MAB in urine. The microwells of the assay plate are coated 
with a purified unlabeled primary antibody. Following this, the plate is incubated with 
unlabeled standards and unknowns. The reaction is allowed to proceed to equilibrium; 
labeled conjugate antigen is then added to the microwells. The conjugate will bind to the 
available binding sites on the primary antibody. The plate is then developed with 
substrate and color change is measured.  
After incubation for a fixed time, separation of bound albumin from free albumin 
is achieved by simple decantation and plate washing. The enzyme activity on the plate is 
measured using enzyme substrate and a chromogen. The absorbency of the color 
developed is read in an EIA colorimetric reader. In a competitive ELISA, there is an 
inverse relationship between the signal obtained and the concentration of the analyte in 
the sample i.e. the more unlabeled antigens in the sample or standard, the lower the 
amount of conjugated antigen bound. The concentration of albumin in the urine is 
determined from a calibration curve.  
The assay literature indicates that sensitivity was calculated by processing ten 
zero calibrator (maximum binding) wells along with a calibration curve. Mean and 
standard deviation were calculated for the absorbance of the ten zero calibrator wells. 
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Apparent sensitivity was found to be 0.24 mg/ml. The antiserum is highly specific for 
human albumin.  
3.3.5.2 Assay Procedural Details 
Kit Contents:   
1.  Microplate with precoated strips  
2.   Albumin Calibrators (5) 
3.   Albumin Enzyme Conjugate  
4.   Controls (2) 
5.   TMB chromogenic substrate  
6.    Stop solution containing sulfuric acid 
 
All reagents and samples should be at room temperature (18-26 °C) prior to use. 
The Control and Positive reference standards packaged ready to use.  Urine specimens 
may be used without pretreatment or dilution. Calibrators, controls and specimen samples 
should be assayed in duplicate.  10 μl of appropriately diluted calibrators, standards and 
specimens were pipetted to each well in duplicate. Next 50 μl diluted enzyme conjugate 
was added to every well. After incubating at room temperature on a plate shaker for an 
hour, the contents of the wells were discarded and the plate was washed 5 times with 250 
μl diluted wash buffer. Next, 100 μl of the diluted antibody was added to each well. After 
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tapping the sides of the plate holder to ensure proper mixing, the plate was covered 
tightly and incubated on a plate shaker for 60 minutes at room temperature. The 
microplate wells were washed 5 times with 250 μl diluted wash buffer. Next, 100 μl of 
the diluted conjugate was added to each well. After tapping the sides of the plate holder 
to ensure proper mixing, the plate was covered tightly and incubated on a plate shaker for 
60 minutes at room temperature. The microplate wells were washed 5 times with 250 μl 
diluted wash buffer. Next, 100 μl of Substrate reagent was added to each well and the 
sides of plate holder tapped to ensure proper mixing. The plate was incubated in the dark 
for 15 minutes at room temperature. 50 μl of Stop Solution was added to each well and 
the absorption was read immediately at 450 nm against 620 nm as a reference. 
 
3.3.5.3 Cross Reactivity 
No cross reactivity to bovine serum albumin, myoglobin, hemoglobin, and alpha 
fetoprotein were noted at significantly high concentration. 
 
3.3.6 Myoglobin  
3.3.6.1 General Principle of the Assay 
The Myoglobin EIA kit used (Myoglobin # 2110 Life Diagnostics, Inc., P.O. Box 
5205, West Chester, PA, 19380) was a sandwich enzyme immunoassay intended for the 
quantitative determination of myoglobin in serum and plasma. The combination of two 
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specific antibodies in the myoglobin ELISA significantly reduces the possibility of false 
negatives. It is for in vitro diagnostic use only. The wells of the microplate are coated 
with polyclonal antibodies directed against myoglobin.  
This ELISA is suitable for the quantitative determination of myoglobin in serum 
and plasma. Although not labeled for use with urine specimens, the technical support 
staff at Life Diagnostics (www.lifediagnostics.com 610-431-7707) asserted the assay was 
fully compatible with urine specimens. 20 μl aliquots of standards, control urine or 
cocaine positive urine specimens (as previously determined by EMIT) are incubated 
simultaneously with two antibodies, resulting in myoglobin molecules being 
„sandwiched‟ between the solid phase and enzyme-linked antibodies. To remove all 
unbound substances, the plate is washed with Barnstead Nanopure Water. The 
chromogenic substrate TMB is added and the plate is incubated for 20 minutes. An acidic 
stop solution is then added to stop the reaction. The intensity of the yellow color is 
directly proportional to the concentration of myoglobin in the sample. A dose response 
curve of the absorbance unit vs. concentration is generated, using results obtained from 
the calibrators. Myoglobin, present in the samples, is determined directly from this curve. 
The lowest detectable level of myoglobin by this assay is estimated to be 5 ng/ml. 
3.3.6.2 Assay Procedural Details 
Kit Contents:   
1. Murine Monoclonal Anti-Myoglobin-coated microtiter wells, 96 wells 
2. Myoglobin Reference Standards (0, 25, 100, 250, 500 and 1000 ng/ml) 
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3. Sample Diluent 
4. Enzyme Conjugate Reagent 
5. TMB Reagent  
6. Stop Solution (1N HCl) 
 
All reagents and samples should be at room temperature (18-26 °C) prior to use. 
The myoglobin reference standards of 0, 25, 100, 250, 500 and 1000ng/ml are provided 
ready to use.  Urine specimens do not require dilution.  20 μl of calibrators, standards and 
specimens were pipetted along with 200 μl of Enzyme Conjugate Reagent to each well in 
duplicate and thoroughly mixed for 30 seconds. After incubating at room temperature for 
45 minutes, the contents of the wells were discarded and the plate was washed 5 times 
with 250 μl Barnstead Nanopure Water.   Next, 100 μl of TMB Substrate reagent was 
added to each well and the sides of plate holder tapped for 5 seconds to ensure proper 
mixing. The plate was incubated for 20 minutes at room temperature. 100 μl of Stop 
Solution was added to each well and the plate was gently mixed for 30 seconds. It is 
important to make sure the blue color is completely changed to yellow before reading the 
absorption. Finally, the absorption was read immediately at 450 nm against 620 nm as a 
reference. 
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3.3.6.3 Cross Reactivity 
No cross reactivity is noted in the assay kit literature.  
 
3.3.7 Heat Shock Protein 90α  
3.3.7.1 General Principle of Assay 
The principle of Heat Shock Protein 90α ELISA Kit used (Heat Shock Protein 
90α Direct ELISA Kit #EKS-895, Assay Designs, Ann Arbor, MI 48108) is a 
quantitative sandwich immunoassay. A 100 μl aliquot of a diluted standard, control urine 
or cocaine positive (as previously determined by EMIT) urine specimen is pipetted into 
the wells and Hsp90α present in a sample is bound to the wells by the immobilized 
antibody. The wells are washed and the Detection Antibody is added. After washing 
away unbound Detection Antibody, HRP-conjugated streptavidin is pipetted to the wells. 
The wells are washed again, a TMB Substrate Reagent is added to the wells and color 
develops in proportion to the amount of Hsp90α bound. The Stop Solution changes the 
color from blue to yellow, and the intensity of the color is measured at 450 nm. 
3.3.7.2 Assay Procedural Details 
Kit contents: 
1. Anti-Hsp90α Microplate  
2. 20X Wash Buffer Concentrate  
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3. Recombinant human Hsp90α Standard 
4. Sample Diluent 
5. HRP Conjugate 
6. HRP Conjugate Diluent 
7. TMB Substrate 
8. Stop Solution 
  All reagents were brought to room temperature prior to use.  Dilute 100 ml of 
Wash Buffer Concentrate into 1900 ml Barnstead Nanopure Water to yield 2000 ml of 1x 
Wash Buffer. Add 27.5 μl of HRP Conjugate into a tube with 11.0 μl 1x HRP Conjugate 
diluent to prepare diluted HRP Conjugate. Mix thoroughly. The standards are prepared by 
adding 2 μl 1 μg/ml Hsp90α stock standard to 500 μl Sample Diluent and performing 
serial dilutions according to Table 4. 
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Table 4. Hsp90α Serial Dilutions 
Tube Volume and Source 
of Hsp90α (μl) 
Sample Diluent  
(μl) 
Final  Hsp90α 
Concentration 
(ng/ml ) 
A 2.0 from the Hsp90α 
standard vial 
500 4 
B 250 from Tube A 250 2 
C 250 from Tube B 250 1 
D 250 from Tube C 250 0.5 
E 250 from Tube D 250 0.25 
F 250 from Tube E 250 0.125 
G 250 from Tube F 250 0.0625 
H 0 250 0 
 
Urine specimens do not require dilution.  100 μl of calibrators, standards and 
specimens were pipetted to each well in duplicate and thoroughly mixed for 30 seconds. 
After incubating at room temperature for 60 minutes, the contents of the wells were 
discarded and the plate was washed 6 times with 300 μl Wash Buffer.   Next, 100 μl of 
HRP Conjugate was added to each well except H1 and H2.  After incubating at room 
temperature for 60 minutes, the contents of the wells were discarded and the plate was 
washed 6 times with 300 μl Wash Buffer.    Next, 100 μl of TMB Substrate reagent was 
added to each well and the sides of plate holder tapped for 5 seconds to ensure proper 
mixing. The plate was incubated for 20 minutes at room temperature. 100 μl of Stop 
Solution was added to each well and the plate was gently mixed for 30 seconds. It is 
important to make sure the blue color is completely changed to yellow before reading the 
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absorption. Finally, the absorption was read immediately at 450 nm against 620 nm as a 
reference.  
 
3.3.7.3 Cross-Reactivity  
Assay Designs‟ Hsp90α ELISA is specific for Hsp90α and will not react with 
Hsp90β. The assay does not cross react with 100ng/mL of Grp94, Hsp60, Hsp70. The 
Hsp90α ELISA has been certified for the detection of human Hsp90α. 
 
3.3.8 Vascular Endothelial Growth Factor  
3.3.8.1 General Principle of Assay 
The principle of Vascular Endothelial Growth Factor ELISA Kit used (Vascular 
Endothelial Growth Factor  ELISA Kit #ELH-VEGF-001, RayBiotech Corporation, 
Norcross, GA 30092) is intended for the quantitative measurement of human VEGF in 
serum, plasma, cell culture supernatants and urine. The assay is based upon the 
competitive binding to antibody of enzyme labeled antigen and unlabeled antigen, in 
proportion to their concentration in the reaction mixture.  
A 20 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is pipetted into the wells and VEGF 
present in a sample is bound to the wells by the immobilized antibody. The wells are 
washed and the Detection Antibody is added. After washing away unbound Detection 
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Antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are washed 
again, a TMB Substrate Reagent is added to the wells and color develops in proportion to 
the amount of VEGF bound. The Stop Solution changes the color from blue to yellow, 
and the intensity of the color is measured at 450 nm. 
3.3.8.2 Assay Procedural Details 
Kit contents: 
1. VEGF Microplate  
2. Wash Buffer Concentrate  
3. Recombinant human VEGF Standard 
4. Assay Diluent A (serum/plasma) 
5. Assay Diluent B (urine and other body fluids) 
6. Detection Antibody VEGF ( biotinylated anti-humanVEGF) 
7. HRP-Streptavidin concentrate  
8. TMB One-Step Substrate Reagent  
9. Stop Solution (2 M sulfuric acid) 
 
 All reagents were brought to room temperature prior to use.  Assay Diluent B is 
used for dilution of culture supernatants and urine; Assay Diluent B is prepared by 
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diluting the contents of the vial 5-fold with Barnstead Nanopure Water. Dilute 20 ml of 
Wash Buffer Concentrate into Barnstead Nanopure Water to yield 400 ml of 1x Wash 
Buffer. Add 100 μl of 1x Assay Diluent B into the vial to prepare a detection antibody 
concentrate. Add 2 μl of HRP-Streptavidin concentrate into a tube with 198.0 μl 1x 
Assay Diluent B to prepare a 100-fold diluted HRP- Streptavidin. Mix thoroughly and 
then pipette 100 μl of prepared 100-fold diluted solution into a tube with 15 ml 1x Assay 
Diluent B to prepare a final 15,000 fold diluted HRP-Streptavidin solution. The standards 
are prepared by adding 60 μl 50 ng/ml VEGF stock standard to 440 μl Assay Diluent B 
and performing serial dilutions according to Table 5: 
 
Table 5. VEGF Serial Dilutions 
Tube Volume and Source 
of VEGF (μl) 
Assay Diluent B 
(μl) 
Final  VEGF 
Concentration 
(pg/ml ) 
A 60 from the VEGF 
standard vial 
440 6000 
B 200 from Tube A 400 2000 
C 200 from Tube B 400 666.7 
D 200 from Tube C 400 222.2 
E 200 from Tube D 400 74.07 
F 200 from Tube E 400 24.69 
G 200 from Tube F 400 8.23 
H 0 400 0 
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100 μl of appropriately diluted calibrators and standards were pipetted to each 
well in duplicate. 100 μl of the specimens were pipetted in duplicate to the appropriate 
wells.  The microplate was covered and incubated for 2.5 hours at room temperature or 
over night at 4°C with gentle shaking. Wash the plate 4 times with 1x Wash Solution. 
After the last wash, the plate was inverted and blotted against clean paper towels. Next, 
100 μl of the diluted biotinylated antibody was added to each well. The plate was 
incubated for 1 hour at room temperature with gentle shaking. The wash cycle was 
repeated. 100 μl of prepared Streptavidin solution was added to each cell.  After tapping 
the sides of the plate holder to ensure proper mixing, the plate was incubated for 45 
minutes at room temperature on a plate shaker. The wash cycle was repeated a final time. 
100 μl of TMB Substrate Reagent was added to each well and the plate was incubated for 
30 minutes at room temperature in the dark with on a plate shaker. The reaction was 
stopped with the addition of 50 μl of Stop Solution to each well. The plate was read at 
450 nm immediately.  A standard curve was generated and the concentration of VEGF in 
each of the specimens was determined. 
 
3.3.8.3 Cross-Reactivity  
This ELISA kit shows no cross-reactivity with any of the following cytokines: 
human Angiogenin, BDNF, BLC, ENA-78, FGF-4, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, 
IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 p70, IL-12 p40, IL-13, IL-15, IL-309, IP-10, G-
CSF, GM-CSF, IFN-γ, Leptin, MCP-1, MCP-2, MCP-3, MDC, MIP-1α, MIP-1 β, MIP-
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1δ, PARC, PDGF, RANTES, SCF, TARC, TGF-β, TIMP-1, TIMP-2, TNF-α, TNF-β, 
TPO  
 
3.3.9 Human Matrix Metalloproteinase 9/Neutrophil Gelatinase Associated Lipocalin  
3.3.9.1 General Principle of Assay 
The principle of Human Matrix Metalloproteinase 9/Neutrophil Gelatinase 
Associated Lipocalin ELISA Kit used (Human Matrix Metalloproteinase 9/Neutrophil 
Gelatinase Associated Lipocalin Direct ELISA Kit #DM9L20, R&D Systems, 
Minneapolis, Minnesota  55413) a sandwich enzyme immunoassay intended for the 
quantitative determination of MMP-9/NGAL in cell culture supernates, serum, plasma, 
urine and saliva. The combination of two specific antibodies in the MMP-9/NGAL 
ELISA significantly reduces the possibility of false negatives. It is for research use only. 
The wells of the microplate are coated with polyclonal antibodies directed against MMP-
9/NGAL.  
A 50 μl aliquot of a standard, control urine or cocaine positive (as previously 
determined by EMIT) urine specimen is incubated with 100 μl Assay Diluent for 3 hours 
at room temperature. The wells are washed 3 times thoroughly and 200 μl of MMP-
9/NGAL conjugate is added. The plate is incubated and washed again before a 
chromogenic substrate added. The color produced is stopped using a dilute acid stop 
solution and the wells read at 450 nm. The intensity of the color developed is inversely 
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proportional to the concentration of drug in the sample. The technique is sensitive to 
0.013 ng/ml. 
3.3.9.2 Assay Procedural Details 
Kit contents: 
1. 96 well micro-plate coated with mouse monoclonal anti-MMP-9/NGAL  
2. MMP-9/NGAL Conjugate solution 
3. Standard containing  20 ng/ml of MMP-9/NGAL , lyophilized 
4. Assay Diluent RD1-87 
5. Calibrator Diluent RD5-10 
6. Color Reagent A 
7. Color Reagent B 
8. Wash Buffer Concentrate 
9. Stop Reagent containing 2 N sulfuric acid  
  
All reagents were brought to room temperature prior to use.  The Wash Buffer 
was prepared by diluting 20 ml of Wash Buffer Concentrate in 480 ml Barnstead 
Nanopure Water.  Color Reagents A and B were mixed together in equal volumes to 
prepare the Substrate Solution. It has to be used within 15 minutes of preparation. The 
lyophilized MMP-9/NGAL standard was reconstituted with 1 ml Barnstead Nanopure 
Water to yield a 20 ng/ml MMP-9/NGAL stock solution. Calibrators were prepared from 
the stock solution according to Table 6: 
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Table 6. NGAL Serial Dilution Table 
Tube  Volume and Source of 
MMP-9/NGAL (μl) 
Calibrator 
Diluent RD5-10 
(μl) 
Final Concentration 
(ng/ml  MMP-9/NGAL) 
A 200 from Stock Solution 200 10 
B 200 from Tube A 200 5 
C 200 from Tube B 200 2.5 
D 200 from Tube C 200 1.25 
E 200 from Tube D 200 0.625 
F 200 from Tube E 200 0.312 
G 0 200 0 
 
100 μl of Assay Diluent RD1-87 was added to each well. 50 μl aliquots of the 
standards, control urine or cocaine positive urine specimens were pipetted in duplicate to 
the appropriate wells. After tapping the sides of the plate holder to ensure proper mixing, 
the plate was incubated for 3 hours at room temperature. The microplate wells were 
aspirated and washed 4 times with 400 μl Barnstead Nanopure water. Following 
incubation, the microplate was inverted and slapped vigorously on absorbent paper to 
ensure all residual moisture was removed. Next, 200 μl of the Conjugate was added to 
each well and the plate was incubated for 1 hour at room temperature.  The aspiration and 
wash cycle was repeated. Next, 200 μl of Substrate reagent was added to each well and 
the sides of plate holder tapped to ensure proper mixing. The plate was incubated in the 
dark for 30 minutes at room temperature. Finally, 50 μl of Stop Solution was added to 
each well, changing the blue color to yellow. 
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Absorbance was measured at a wavelength of 450 nm. A standard curve was 
produced and the concentration of MMP-9/NGAL in each of the specimens was 
determined. 
No significant cross-reactivity has been noted. 
 
3.3.10 Pro-atrial natriuretic peptide (1-98)  
3.3.10.1 General Principle of Assay 
The pro-atrial natriuretic peptide (1-98) EIA kit used (proANP Direct EIA Kit # 
04-BI-20892, ALPCO Diagnostics, Salem, NH 03079) follows the typical direct binding 
scenario. It is appropriate for research use only. The wells of the microplate are coated 
with polyclonal antibodies directed against proANP. The kit may be used with urine with 
no pretreatment.  
A 10 μl aliquot of a standard, control urine or cocaine positive (as previously 
determined by EMIT) urine specimen is added to each well except the blank. 200 μl of 
Conjugate is added to all the wells, except the blanks, and incubated in the dark for 3 
hours at room temperature. The wells are washed 5 times thoroughly and 200 μl of 
Substrate is added. The plate is incubated the reaction is stopped using a dilute acid stop 
solution. Finally, measure the absorbance at 450 nm with a reference of 620 nm. The 
intensity of the color developed is proportional to the concentration of drug in the sample.  
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3.3.10.2 Assay Procedural Details 
Kit Contents: 
1. Polyclonal sheep anti proANP Coated Microwell Plate 
2. Conjugate (polyclonal anti proANP antibody –HRPO) 
3. ProANP standards, lyophilized 
4. Control, lyophilized 
5. Wash Buffer Concentrate    
6. Assay Buffer   
7. TMB Substrate    
8. Stop Solution (Sulfuric Acid)    
All reagents must reach room temperature before use. The Control and Positive 
reference standards of 0, 0.63, 1.25, 2.5, 5.0 and 10.0 nmol/l are lyophilized and required 
reconstitution with 250 μl Barnstead Nanopure water. Calibrators, controls and specimen 
samples should be assayed in duplicate.  Once the procedure has been started, all steps 
should be completed without interruption. The conjugate (polyclonal anti proANP 
antibody –HRPO) was provided ready to use. The wash buffer was prepared by diluting 
the wash buffer concentrate 1:20 with Barnstead Nanopure water (50 ml of the wash 
buffer concentrate in 950 ml of water).   
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10 μl of each calibrator, treated control urine and treated cocaine positive urine 
(as determined by EMIT) were pipetted into correspondingly labeled wells in duplicate.  
Next, 200 μl of the conjugate working solution was pipetted into each well, except the 
blanks.  The plate was incubated for 3 hours at room temperature in the dark.  The wells 
were aspirated and washed 5 times with 300 μl of diluted wash buffer per well.  The plate 
was tapped firmly against absorbent paper to ensure complete drying.  200 μl of TMB 
substrate was pipetted into each well and the plate was incubated on a plate shaker for 30 
minutes at room temperature in the dark. 50 μl of stopping solution was added to each 
well and the plate was read at 450nm with a reference of 620 nm.   A standard curve was 
produced and the concentration of proANP in each of the specimens was determined. 
3.3.10.3 Cross-Reactivity 
proANP (1-30) < 1% 
proANP (31-67) <1% 
proANP (79-98) <1%   
alpha ANP (99-126) <1% 
proBNP (8-29) <1% 
 proBNP (32-57) <1% 
 proCNP (1-19) <1% 
proCNP (30-50) <1% 
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 proCNP (51-97) <1% 
The assay also detects mouse and rat proANP (1-98). 
 
3.3.11 Interleukin 1α  
3.3.11.1 General Principle of the Assay 
The Interleukin 1α EIA kit used (Interleukin 1α  #583301, Cayman Chemicals, 
Ann Arbor, MI 48108) is a sandwich enzyme immunoassay intended for the quantitative 
determination of Interleukin 1α  in serum and plasma. Cayman Chemical Technical 
Support verified the assay was compatible with urine specimens so long as the standards 
are diluted with an appropriate sample matrix blank (SMB). Synthetic Urine from 
Immunalysis (Synthetic Urine with Creatinine Dry Powder #SUP-5, Immunalysis 
Corporation, Pomona, CA  91767) was used for the sample matrix blank. The 
combination of two specific antibodies in the Interleukin 1α ELISA significantly reduces 
the possibility of false negatives. It is for research use only. The wells of the microplate 
are coated with polyclonal antibodies directed against Interleukin 1α.  
A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is added to the appropriate wells in 
duplicate. Next, 100 μl of Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate is added 
to all wells except the blanks and incubated for overnight at 4 °C. The plate is then 
washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s 
Reagent is added to each well and the plate is incubated in the dark. The reaction is 
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monitored for several hours until the S1 wells are visibly yellow. The intensity of the 
color that forms is directly proportional to the concentration of Interleukin-1 α in the 
sample. A dose response curve of the absorbance (at 405 nm) unit vs. concentration is 
generated. Interleukin-1 α, present in the patient samples, is determined directly from this 
calibration curve. The assay is sensitive to 1.5 pg/ml Interleukin-1 α. 
 
3.3.11.2 Assay Procedural Details 
Kit Contents:   
1.  Microplate with precoated strips  
2.   Interleukin-1 α standard 
3.   Non-specific Mouse Serum 
4.   Sample Matrix Blank for plasma, serum (cannot be used for this assay) 
5.   Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate 
6.   EIA Buffer Concentrate 
7.   Wash Buffer Concentrate  
8.    Tween 
9.    Ellman‟s Reagent 
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All reagents and samples should be at room temperature (18-26 °C) prior to use. 
The EIA Buffer concentrate was reconstituted with 90 ml of Barnstead Nanopure water. 
The Wash Buffer was prepared by bringing 5 ml of wash buffer concentrate to a total 
volume of 2 L with Barnstead Nanopure water and then adding 1 ml Tween.  The 
Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate was reconstituted with 10 ml of 
EIA buffer. The urine specimens were used without any dilution. Interleukin-1 α 
standards required reconstitution with 2 ml EIA Buffer prior to dilution with SMB. This 
initial dilution yielded a stock solution of 5 ng/ml Interleukin-1 α. The Immunalysis 
Synthetic Urine served as the SMB; the lyophilized urine was reconstituted with 
Barnstead Nanopure water prior to use. 4.5 L of Nanopure water were added to the 
contents of the pouch. The solution was stirred until the lyophilized urine dissolved 
completely. The total volume was adjusted to 5 L with Nanopure water. The synthetic 
urine is stable for 1 year when stored at 4°C.   
The Interleukin-1 α standards were prepared as described in Table 7: 
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Table 7. Concentration of Interleukin-1 α Standards 
Tube Volume and Source of 
Interleukin-1 α (μl) 
Sample Matrix 
Buffer (μl) 
Final Concentration 
(pg/ml Interleukin-1α) 
A 50 from Stock Solution Dilute to 1 ml total 250 
B 500 from Tube A 500 125 
C 500 from Tube B 500 62.5 
D 500 from Tube C 500 31.25 
E 500 from Tube D 500 15.6 
F 500 from Tube E 500 7.8 
G 500 from Tube F 500 3.9 
H 0 500 0 
 
Calibrators, controls and specimen samples should be assayed in duplicate.  100 
μl of appropriately diluted calibrators, standards and specimens were pipetted to each 
well in duplicate. . Next, 100 μl of Acetylcholinesterase: Interleukin-1 α Fab‟ Conjugate 
is added to all wells except the blanks and incubated for overnight at 4 °C. The plate is 
then washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of 
Ellman‟s Reagent is added to each well and the plate is incubated in the dark. The 
reaction is monitored for several hours until the S1 wells are visibly yellow. The intensity 
of the color that forms is directly proportional to the concentration of Interleukin-1 α in 
the sample. The absorption was read immediately at 405 nm. 
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3.3.12 Interleukin 1β  
3.3.12.1 General Principle of the Assay 
The Interleukin 1β EIA kit used (Interleukin 1β  #583311, Cayman Chemicals, 
Ann Arbor, MI 48108) is a sandwich enzyme immunoassay intended for the quantitative 
determination of Interleukin 1β  in serum and plasma. Cayman Chemical Technical 
Support verified the assay was compatible with urine specimens so long as the standards 
are diluted with an appropriate sample matrix blank (SMB). Synthetic Urine from 
Immunalysis (Synthetic Urine with Creatinine Dry Powder #SUP-5, Immunalysis 
Corporation, Pomona, CA  91767) was used for the sample matrix blank. The 
combination of two specific antibodies in the Interleukin 1β ELISA significantly reduces 
the possibility of false negatives. It is for research use only. The wells of the microplate 
are coated with polyclonal antibodies directed against Interleukin 1β.  
A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is added to the appropriate wells in 
duplicate. Next, 100 μl of Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate is added 
to all wells except the blanks and incubated for overnight at 4 °C. The plate is then 
washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s 
Reagent is added to each well and the plate is incubated in the dark. The reaction is 
monitored for several hours until the S1 (250 pg/ml) wells are visibly yellow. The 
intensity of the color that forms is directly proportional to the concentration of 
Interleukin-1 β in the sample. A dose response curve of the absorbance (at 405 nm) unit 
vs. concentration is generated. Interleukin-1 β, present in the patient samples, is 
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determined directly from this calibration curve. The assay is sensitive to 1.5 pg/ml 
Interleukin-1 β. 
 
3.3.12.2 Assay Procedural Details 
Kit Contents:   
1.  Microplate with precoated strips  
2.   Interleukin-1 β standard 
3.   Non-specific Mouse Serum 
4.   Sample Matrix Blank for plasma, serum (cannot be used for this assay) 
5.   Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate 
6.   EIA Buffer Concentrate 
7.   Wash Buffer Concentrate  
8.    Tween 
9.    Ellman‟s Reagent 
All reagents and samples should be at room temperature (18-26 °C) prior to use. 
The EIA Buffer concentrate was reconstituted with 90 ml of Barnstead Nanopure water. 
The Wash Buffer was prepared by bringing 5 ml of wash buffer concentrate to a total 
volume of 2 L with Barnstead Nanopure water and then adding 1 ml Tween.  The 
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Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate was reconstituted with 10 ml of 
EIA buffer. The urine specimens were used without any dilution. Interleukin-1 β 
standards required reconstitution with 2 ml EIA Buffer prior to dilution with SMB. This 
initial dilution yielded a stock solution of 5 ng/ml Interleukin-1 β. The Immunalysis 
Synthetic Urine served as the SMB; the lyophilized urine was reconstituted with 
Barnstead Nanopure water prior to use. 4.5 L of Nanopure water were added to the 
contents of the pouch. The solution was stirred until the lyophilized urine dissolved 
completely. The total volume was adjusted to 5 L with Nanopure water. The synthetic 
urine is stable for 1 year when stored at 4°C.   
The Interleukin-1 β standards were prepared as described in Table 8: 
 Table 8. Concentration of Interleukin-1 β Standards  
Tube  Volume and Source 
of Interleukin-1 β (μl) 
Sample Matrix 
Buffer (μl) 
Final Concentration 
(pg/ml Interleukin-1β) 
A 50 from Stock Solution Dilute to 1 ml total 250 
B 500 from Tube A 500 125 
C 500 from Tube B 500 62.5 
D 500 from Tube C 500 31.25 
E 500 from Tube D 500 15.6 
F 500 from Tube E 500 7.8 
G 500 from Tube F 500 3.9 
H 0 500 0 
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Calibrators, controls and specimen samples should be assayed in duplicate.  100 
μl of appropriately diluted calibrators, standards and specimens were pipetted to each 
well in duplicate. . Next, 100 μl of Acetylcholinesterase: Interleukin-1 β Fab‟ Conjugate 
is added to all wells except the blanks and incubated for overnight at 4 °C. The plate is 
then washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of 
Ellman‟s Reagent is added to each well and the plate is incubated in the dark. The 
reaction is monitored for several hours until the S1 wells are visibly yellow. The intensity 
of the color that forms is directly proportional to the concentration of Interleukin-1 β in 
the sample. The absorption was read immediately at 405 nm. 
 
3.3.13 Interleukin 6  
3.3.13.1 General Principle of the Assay 
The Interleukin 6 EIA kit used (Interleukin 6  #583361, Cayman Chemicals, Ann 
Arbor, MI 48108) is a sandwich enzyme immunoassay intended for the quantitative 
determination of Interleukin 6  in serum and plasma. Cayman Chemical Technical 
Support verified the assay was compatible with urine specimens so long as the standards 
are diluted with an appropriate sample matrix blank (SMB). Synthetic Urine from 
Immunalysis (Synthetic Urine with Creatinine Dry Powder #SUP-5, Immunalysis 
Corporation, Pomona, CA  91767) was used for the sample matrix blank. The 
combination of two specific antibodies in the Interleukin 6 ELISA significantly reduces 
the possibility of false negatives. It is for research use only. The wells of the microplate 
are coated with polyclonal antibodies directed against Interleukin 6.  
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A 100 μl aliquot of a diluted standard, control urine or cocaine positive (as 
previously determined by EMIT) urine specimen is added to the appropriate wells in 
duplicate. Next, 100 μl of Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate is added to 
all wells except the blanks and incubated for overnight at 4 °C. The plate is then washed 
5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s Reagent 
is added to each well and the plate is incubated in the dark. The reaction is monitored for 
several hours until the S1 (250 pg/ml) wells are visibly yellow. The intensity of the color 
that forms is directly proportional to the concentration of Interleukin-6 in the sample. A 
dose response curve of the absorbance (at 405 nm) unit vs. concentration is generated. 
Interleukin 6 present in the patient samples is determined directly from this calibration 
curve. The assay is sensitive to 7.8 pg/ml Interleukin-6. 
 
3.3.13.2 Assay Procedural Details 
Kit Contents:   
1.  Microplate with precoated strips  
2.   Interleukin-6 standard 
3.   Non-specific Mouse Serum 
4.   Sample Matrix Blank for plasma, serum (cannot be used for this assay) 
5.   Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate 
6.   EIA Buffer Concentrate 
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7.   Wash Buffer Concentrate  
8.    Tween 20 
9.    Ellman‟s Reagent 
 
All reagents and samples should be at room temperature (18-26 °C) prior to use. 
The EIA Buffer concentrate was reconstituted with 90 ml of Barnstead Nanopure water. 
The Wash Buffer was prepared by bringing 5 ml of wash buffer concentrate to a total 
volume of 2 L with Barnstead Nanopure water and then adding 1 ml Tween.  The 
Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate was reconstituted with 10 ml of EIA 
buffer. The urine specimens were used without any dilution. Interleukin-6 standards 
required reconstitution with 2 ml EIA Buffer prior to dilution with SMB. This initial 
dilution yielded a stock solution of 5 ng/ml Interleukin-6. The Immunalysis Synthetic 
Urine served as the SMB; the lyophilized urine was reconstituted with Barnstead 
Nanopure water prior to use. 4.5 L of Nanopure water were added to the contents of the 
pouch. The solution was stirred until the lyophilized urine dissolved completely. The total 
volume was adjusted to 5 L with Nanopure water. The synthetic urine is stable for 1 year 
when stored at 4°C.   
The Interleukin-6 standards were prepared as described in the table below (Table 
9): 
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Table 9. Concentration of Interleukin-6 Standards 
Tube  Volume and Source of 
Interleukin-6 (μl) 
Sample Matrix 
Buffer (μl) 
Final Concentration 
(pg/ml Interleukin-6) 
A 50 from Stock Solution Dilute to 1 ml total 250 
B 500 from Tube A 500 125 
C 500 from Tube B 500 62.5 
D 500 from Tube C 500 31.3 
E 500 from Tube D 500 15.6 
F 500 from Tube E 500 7.8 
G 500 from Tube F 500 3.9 
H 0 500 0 
 
Calibrators, controls and specimen samples should be assayed in duplicate.  100 
μl of appropriately diluted calibrators, standards and specimens were pipetted to each 
well in duplicate. . Next, 100 μl of Acetylcholinesterase: Interleukin-6 Fab‟ Conjugate is 
added to all wells except the blanks and incubated for overnight at 4 °C. The plate is then 
washed 5 times with Wash Buffer to remove all unbound substances. 200 μl of Ellman‟s 
Reagent is added to each well and the plate is incubated in the dark. The reaction is 
monitored for several hours until the S1 (250 pg/ml standard) wells are visibly yellow. 
The intensity of the color that forms is directly proportional to the concentration of 
Interleukin-6 in the sample. The absorption was read immediately at 405 nm. 
Crossreactivity with the other interleukins is limited. 
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Chapter 4.0 
Results 
 
Results were analyzed using a Student‟s t test for significance (JMP Start 
Statistics, Release 4.0.4 SAS Institute, 2001) was used to compare biomarker 
concentration in the male and female, control and cocaine positive specimens. Because 
the data was not parametric, the Wilcoxon Rank Sums and Mann Whitney U tests were 
also used to test the means. In addition, the Tukey-Kramer HSD test was also used to 
analyze the means. The results were the same regardless of the analysis performed. 
4.1 Gender 
4.1.1 Assay results in Male and Female Control Urines  
A summary of the differences in marker expression between male and female 
control urine specimens is presented in Table 10. The individual results are standardized 
and expressed per milligram creatinine. The mean aldosterone concentration was 
statistically significantly (p=0.0223) in female urine when compared to male urine 
specimens.  The same was true for IL1 α (p=.0007) and IL1 β (p=.0198).  The results for 
hsCRP (p=.0662) and MPO (p=.0562) are suggestive of statistical significance. There 
was no statistically significant difference in the other biomarkers. 
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Table 10. Comparison of Assay results in Male and Female Control Urines 
Assay 
Control 
Male Female p 
Total Protein (pg) 32.2 + 12.1 65.9+20.8 .2294 
Aldosterone (pg) 1907.7 + 356.7 4917.96+1159.9 .0223* 
hsCRP  (ng) 0.78+ .6 202.3+103.0 .0662 
Myeloperoxidase (ng) 20.5+ 7.9 187.1+81.3 .0562 
Microalbumin  (ug) 18.4+ 7.3 41.2+14.4 .1763 
Hsp90 α (ng) 0.92+ .4 0.3+.2 .2133 
VEGF (pg) 2453.0+ 972.5 3286.2+1402.6 .6205 
proANP   (nmol) 0.3+.1 0.34+.1 .5482 
Myoglobin  (ng) 15.5+9.8 26.5+9.1 .393 
NGAL  (ng) 0.08+.1 12.5+9.8 .2213 
IL6  (pg) 0.86+.4 7.52+4.4 .1532 
IL1 α  (pg) 3.8+3.8 56.9+12.5 .0007* 
IL1 β   (pg) 2.2+1.0 6.6+1.4 .0198* 
*significant at p<0.05 
values expressed as mean + standard error of the mean (SEM) 
 
4.1.2 Assay results in Male and Female Cocaine Positive Urines  
A summary of the differences in marker expression between male and female 
cocaine positive urine specimens is presented in Table 11. The individual results are 
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standardized and expressed per milligram creatinine. The results for Hsp90α (p=.0650) 
are suggestive of statistical significance. There was no statistically significant difference 
in the other biomarkers. 
Table 11. Comparison of Assay results in Male and Female Cocaine Positive Urines 
Assay 
Cocaine Positive 
Male Female p 
Total Protein (pg) 66.9+22.4 47.4+3.2 .4612 
Aldosterone (pg) 3331.8+399.8 3463.6+723.2 .8600 
hsCRP  (ng) 42.1+44.4 47.4+34.3 .9275 
Myeloperoxidase (ng) 25.15+9.7 52.1+22.1 .2140 
Microalbumin  (ug) 32.9+9.7 40.5+10.2 .5995 
Hsp90 α (ng) 0.9+.3 0.02+.1 .0650 
VEGF (pg) 2900.9+1168 1308.4+351.9 .2535 
proANP   (nmol) 0.5+.1 0.3+.1 .3612 
Myoglobin  (ng) 36.9+4.8 45.9+9.8 .3586 
NGAL  (ng) 0.3+.12 20.2+12.0 .1534 
IL6  (pg) 3.8+ 8.9 6.3+4.6 .6521 
IL1 α  (pg) 1.74+1.07 26.2+12.3 .0907 
IL1 β   (pg) 
2.5+.5 9.5+3.4 .0846 
* significant at p<0.05 
values expressed as mean + standard error of the mean (SEM) 
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4.2 Cocaine 
4.2.1 Assay Results in Male Control and Cocaine Positive Urine Specimens  
A summary of the differences in marker expression between control and cocaine 
positive male urine specimens is presented in Table 12. The individual assay results are 
standardized and expressed per milligram creatinine. The mean aldosterone concentration 
was significantly higher (p=0.0095) in cocaine positive urine when compared to control 
urine specimens.  The mean myoglobin concentration was significantly higher 
(p=0.0332) in cocaine positive urine when compared to control urine specimens.  There 
was no statistically significant difference in the other biomarkers. 
 
4.2.2 Assay Results in Female Control and Cocaine Positive Urine Specimens  
A summary of the differences in marker expression in control and cocaine 
positive female urine specimens is presented in Table 13. The individual results are 
standardized and expressed per milligram creatinine. There were no statistically 
significant differences between the control and cocaine positive means for any of the 
assays. 
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Table 12. Comparison of Assay Results in Male Control and Cocaine Positive Urine  
Assay 
Male 
Control Cocaine Positive p 
Total Protein (pg) 32.2 + 12.1 66.9+22.4 0.2377 
Aldosterone (pg) 1907.7 + 356.7 3331.8+399.8 0.0095* 
hsCRP  (ng) 0.78+ .6 42.1+44.4 0.3668 
Myeloperoxidase (ng) 20.5+ 7.9 25.15+9.7 0.6985 
Microalbumin  (ug) 18.4+ 7.3 32.9+9.7 0.2474 
Hsp90 α (ng) 0.92+ .4 0.9+.3 0.967 
VEGF (pg) 2453.0+ 972.5 2900.9+1168 0.7555 
proANP   (nmol) 0.3+.1 0.5+.1 0.1276 
Myoglobin  (ng) 15.5+9.8 36.9+4.8 0.0332* 
NGAL  (ng) 0.08+.1 0.3+.12 0.0984 
IL6  (pg) 
0.86+.4 3.8+ 8.9 0.1909 
IL1 α  (pg) 3.8+3.8 1.74+1.07 0.6247 
IL1 β   (pg) 
2.2+1.0 2.5+.5 0.8124 
* significant p < .05 
values expressed as mean + standard error of the mean (SEM) 
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Table 13. Comparison of Assay Results in Female Control and Cocaine Positive Urine  
Assay 
Female 
Control Cocaine Positive p 
Total Protein (pg) 
65.9+20.8 47.4+3.2 0.4443 
Aldosterone (pg) 
4917.96+1159.9 3463.6+723.2 0.3321 
hsCRP  (ng) 
202.3+103.0 47.4+34.3 0.2147 
Myeloperoxidase (ng) 
187.1+81.3 52.1+22.1 0.1684 
Microalbumin  (ug) 
41.2+14.4 40.5+10.2 0.9677 
Hsp90 α (ng) 
0.3+.2 0.02+.1 0.5478 
VEGF (pg) 
3286.2+1402.6 1308.4+351.9 0.2366 
proANP   (nmol) 
0.34+.1 0.3+.1 0.9436 
Myoglobin  (ng) 
26.5+9.1 45.9+9.8 0.1657 
NGAL  (ng) 
12.5+9.8 20.2+12.0 0.6309 
IL6  (pg) 
7.52+4.4 6.3+4.6 0.8475 
IL1 α  (pg) 
56.9+12.5 26.2+12.3 0.0963 
IL1 β   (pg) 
6.6+1.4 9.5+3.4 0.461 
* significant p < .05 
values expressed as mean + standard error of the mean (SEM) 
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4.3 Tables 
Table 14. Male and Female Control and Cocaine Positive Urine Specimen Comparison 
Assay 
Male Female 
Control Cocaine Positive p Control Cocaine Positive p 
Total Protein (pg) 
32.2 + 12.1 66.9+22.4 0.2377 65.9+20.8 47.4+3.2 0.4443 
Aldosterone (pg) 
1907.7 + 356.7 3331.8+399.8 0.0095* 4917.96+1159.9 3463.6+723.2 0.3321 
hsCRP  (ng) 
0.78+ .6 42.1+44.4 0.3668 202.3+103.0 47.4+34.3 0.2147 
Myeloperoxidase (ng) 
20.5+ 7.9 25.15+9.7 0.6985 187.1+81.3 52.1+22.1 0.1684 
Microalbumin  (ug) 
18.4+ 7.3 32.9+9.7 0.2474 41.2+14.4 40.5+10.2 0.9677 
Hsp90 α (ng) 
0.92+ .4 0.9+.3 0.967 0.3+.2 0.02+.1 0.5478 
VEGF (pg) 
2453.0+ 972.5 2900.9+1168 0.7555 3286.2+1402.6 1308.4+351.9 0.2366 
proANP   (nmol) 
0.3+.1 0.5+.1 0.1276 0.34+.1 0.3+.1 0.9436 
Myoglobin  (ng) 
15.5+9.8 36.9+4.8 0.0332* 26.5+9.1 45.9+9.8 0.1657 
NGAL  (ng) 
0.08+.1 0.3+.12 0.0984 12.5+9.8 20.2+12.0 0.6309 
IL6  (pg) 
0.86+.4 3.8+ 8.9 0.1909 7.52+4.4 6.3+4.6 0.8475 
IL1 α  (pg) 
3.8+3.8 1.74+1.07 0.6247 56.9+12.5 26.2+12.3 0.0963 
IL1 β   (pg) 
2.2+1.0 2.5+.5 0.8124 6.6+1.4 9.5+3.4 0.461 
* significant p < .05 
values expressed as mean + standard error of the mean (SEM) 
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Table 15. Control and Cocaine Positive Male and Female Urine Specimen Comparison 
Assay 
Control Cocaine Positive 
Male Female p Male Female p 
Total Protein (pg) 
32.2 + 12.1 65.9+20.8 .2294 66.9+22.4 47.4+3.2 .4612 
Aldosterone (pg) 
1907.7 + 356.7 4917.96+1159.9 .0223* 3331.8+399.8 3463.6+723.2 .8600 
hsCRP  (ng) 
0.78+ .6 202.3+103.0 .0662 42.1+44.4 47.4+34.3 .9275 
Myeloperoxidase (ng) 
20.5+ 7.9 187.1+81.3 .0562 25.15+9.7 52.1+22.1 .2140 
Microalbumin  (ug) 
18.4+ 7.3 41.2+14.4 .1763 32.9+9.7 40.5+10.2 .5995 
Hsp90 α (ng) 
0.92+ .4 0.3+.2 .2133 0.9+.3 0.02+.1 .0650 
VEGF (pg) 
2453.0+ 972.5 3286.2+1402.6 .6205 2900.9+1168 1308.4+351.9 .2535 
proANP   (nmol) 
0.3+.1 0.34+.1 .5482 0.5+.1 0.3+.1 .3612 
Myoglobin  (ng) 
15.5+9.8 26.5+9.1 .393 36.9+4.8 45.9+9.8 .3586 
NGAL  (ng) 
0.08+.1 12.5+9.8 .2213 0.3+.12 20.2+12.0 .1534 
IL6  (pg) 
0.86+.4 7.52+4.4 .1532 3.8+ 8.9 6.3+4.6 .6521 
IL1 α  (pg) 
3.8+3.8 56.9+12.5 .0007* 1.74+1.07 26.2+12.3 .0907 
IL1 β   (pg) 
2.2+1.0 6.6+1.4 .0198* 2.5+.5 9.5+3.4 .0846 
* significant p < .05 
values expressed as mean + standard error of the mean (SEM) 
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Chapter 5.0 
Discussion 
 
 There are well-documented gender based differences in the etiology and 
pathophysiology in many disease states [62, 64, 67, 70, 71, 73-75, 78, 93, 127-142]. 
Gender differences are well known to exist for many important markers of disease 
including triglycerides, enzymes such as AST and SGOT, HDL, uric acid, creatine and 
hormones. While blood has remained the medium of clinical preference, toxicological 
screens however are frequently done on urine. Unlike serum and plasma, urine typically 
lacks interference from clotting and compounds such as proteases [143]. It is well 
documented that many proteins are expressed in urine, particularly during certain disease 
states; in fact, the human urinary proteome contains more than 1500 proteins [144]. Little 
is known about the differences in urinary marker expression between males and females.  
 Recently, the use of urine as a medium to analyze the expression of many proteins 
in the body has become more acceptable [145]. Urinary analysis takes advantage of 
protein cell and tissue specificity and their alteration over time in response to different 
situations [146]. The proteins and peptides in urine are referred to as the urinary 
proteome; variation in the levels of these protein biomarkers has been associated with 
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certain pathological states. Markers in the urinary proteome have been validated for 
inflammation, oxidative stress, cardiovascular dysfunction and renal disorders [144, 145].  
 Inflammation is a very common, non-specific form of pathophysiology; 
myeloperoxidase, C reactive protein, and IL 6 are markers of acute and systemic 
inflammation [147, 148]. MPO is also commonly used as an endpoint of oxidative stress 
[149]. IL-1α and IL-1β are immunoregulatory cytokines that favor inflammation; 
increased expression is associated with fever, inflammation, tissue destruction, shock and 
death. The difference between male and female CRP and MPO were close to statistical 
significance in control urine. IL-1α and IL-1β expression is also associated with 
autoimmune disorders. It is possible that the gender disparity seen in autoimmune 
disorders could reflect a chronic, low-level activation of the immune system that might be 
seen in elevated interleukins [150]. In control urine, female IL-1α and IL-1β were higher 
than male values by a statistically significant amount. Elevated concentrations of 
interleukins upregulate acute phase proteins such as IL 6 and CRP.  Albuminuria is 
associated with cardiovascular disease, kidney dysfunction and DM [151-153]. Urinary 
NGAL expression is linked to nephritis and urinary tract infections [105, 154]. Creatinine 
is a general marker of myolysis and kidney disease [155, 156]. Myoglobin is another 
marker of myolysis; it was considered the gold standard of cardiac markers prior to the 
characterization of troponin. There were no significant gender based results in the 
analysis of IL6, microalbumin, NGAL or myoglobin. There was a statistically significant 
increase in myoglobin demonstrated in male cocaine positive urine specimens as 
compared to male control urine. 
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 Oxidative stress has been implicated in a variety of inflammatory processes. For 
example, increased vascular oxidative stress leads to endothelial dysfunction and 
hypertension. VEGF, a marker of angiogenesis, may also be elevated by endothelial 
dysfunction [157]. Microalbumin expression is enhanced by many of the same 
pathophysiological conditions as VEGF. It is linked to increased cardiovascular and renal 
risk factors. Neither microalbumin nor VEGF were statistically significant in any 
analysis. Increased oxidative stress is implicated in the activation of the RAS and 
subsequent elevations in aldosterone.  Aldosterone is a renal hormone in the RAS 
secreted in response to hypotension. Aldosterone was higher in female control urine, 
when compared to male control urine, by a statistically significant amount. There was 
also a statistically significant increase in aldosterone in male cocaine positive urine when 
compared to male control urine specimens. Increased cardiac concentrations have been 
linked to heart failure. It has been observed that inhibition of the RAS results in a decline 
in ROS production [65, 66]. proANP is a hypotensive peptide that counteracts the RAS 
by inhibiting the release of hormones such as aldosterone and renin [158]. Increased ANP 
levels are detected in adult congestive heart failure, chronic renal failure and in severe 
essential hypertension [158, 159]. No statistically significant results were seen in this 
study in any analysis of proANP. 
 While there are noted gender based differences in the etiology of cardiac and 
vascular disease, particularly in the area of comorbid conditions, underlying blood 
pressure and resultant mortality, the basis of the gender dimorphism is unclear. Clearly 
hormones may play an important role as cardiac muscle and vascular tissue are 
influenced by hormones such as estrogen and testosterone [1, 9, 10, 12, 59-61]. The 
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relationship between inflammatory cytokines and gender has not been clearly elucidated, 
although some differences in serum levels of risk markers, including lipids and acute 
phase proteins have been noted [6, 27, 29, 30, 80-82]. Studies suggest there may be 
gender related differences in the regulation of IL-1 so it is possible that the interleukins 
serve different functions depending on gender [160, 161]. Mean concentrations of IL 1α 
and IL 1β were significantly higher in the control urine of women than in men.  
 IL-6 has both pro and anti-inflammatory roles depending on the target cell. It has 
been dubbed a „myokine‟, a cytokine produced by muscle and elevated during muscle 
contraction and has been found to act synergistically with both IL-1 subunits [162, 163]. 
Elevations in IL-6 frequently precede increases in CRP [164]. It may be possible that 
alterations in urinary IL-6 expression were transitory in our study. This could explain the 
failure to detect a significant difference in IL6 between control and metabolite positive 
urine specimens.  
Women tend to have slightly higher serum CRP than men with the same BMI and 
age; however, these differences are not pronounced enough to warrant gender-dependent 
reference ranges [135, 165]. The role of gender in predisposition to oxidative stress has 
yet to be determined. The clinical and prognostic relevance of these differences requires 
further research. CRP is an acute phase inflammatory marker considered to be a reliable 
prognostic indicator of atherosclerosis and acute myocardial infarction (AMI) [61, 82, 
86]. Urinary levels peak approximately 24 hours following the inflammatory event and 
are undetectable within 13 to 16 hours. The differences between male and female CRP 
means in control urines in this study were just outside of statistical significance 
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(p=0.0662).  Cocaine metabolites can remain in the urine for 48 to 72 hours following 
acute use, whereas CRP in urine quickly wanes. The results from this study suggest that 
CRP levels in urine may not be a reliable prognostic indicator for these 
pathophysiological processes at least under the conditions of this study. 
 
As a measure of leukocyte infiltration, the concentration of MPO may increase 
significantly in an acute infection such as those of the urinary tract Elevated MPO is 
linked to adverse outcomes in acute coronary syndromes and can be used to identify 
patients at risk for cardiac events in the absence of cardiac necrosis [54, 87]. Elevated 
MPO levels have been shown to independently predict increased risk of major adverse 
cardiac events including MI at 30 days and 6 months [166]. The predictive value of this 
marker has not been fully characterized; however, it is associated with long term adverse 
cardiac events as well. The differences between male and female MPO means in control 
urines in this study were just outside of statistical significance (p=0.0562).   
 
 Cocaine is well absorbed mucosally and metabolized almost immediately by 
serum cholinesterase [56]. The serum half-life of cocaine is less than an hour. The 
pharmocodynamics do not change substantially for different routes of entry despite 
differences in onset of action, peak absorbance and duration of effect [167].  BE and 
EME are the primary metabolites; up to 50% of cocaine is transformed to BE and 30 to 
40% is metabolized to EME.  Although neither metabolite is pharmacologically active, 
both BE and EME been shown to elevate blood pressure [43].  The intense cardiotoxic 
interaction between ethanol and cocaine was the primary reason for excluding ethanol 
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positive urine specimens from analysis. CE has a significantly longer half life than both 
cocaine and BE; inclusion of specimens that could potentially contain CE could affect the 
expression of biomarkers such as myoglobin, CRP and MPO.  
 Cocaine increases intracellular oxygen demand, elevates heart rate and arterial 
blood pressure [35, 168]. Cocaine use has been linked to hypertension and tachycardia, 
although the effects on heart rate are variable [42, 169]. Increases in myocardial oxygen 
demand are associated with the induction of oxidative stress. Cocaine use has been 
further shown to enhance endothelial permeability, which may be linked to subclinical 
cardiovascular disease, vascular dysfunction, kidney disease, hypertension, nephrotic 
syndrome, glomerulonephritis, interstitial nephritis, and rhabdomyolysis [34, 49, 58, 
115]. 
Atherosclerosis, an endothelial cell dysfunction,  is characterized by the 
development of abnormal vascular responses and the expression of proinflammatory and 
prothrombotic factors [50]. MPO is expressed as a result of atherosclerotic lesions such 
as those seen in chronic cocaine use. Females had a significantly higher mean 
concentration than did males. Estradiol has been suggested as a potential endogenous 
substrate for MPO in plasma [88]. As with CRP, the differences between male and 
female MPO means in control urines were just outside statistical significance (p=0.0562).  
 
 Examination of male and female cocaine positive urine specimens yielded no 
statistically significant differences. While the male mean Hsp90α was higher than the 
female mean (p=.0650), this result is not statistically significant. It should be noted that 
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several markers that exhibited significant differences in control urines were no longer 
significant in cocaine positive urine. In cocaine positive urine, the mean male aldosterone 
was significantly higher than the male control mean (p=0.0095). The female cocaine 
positive aldosterone mean was somewhat lower than the control mean although the 
difference was not significant. Mean concentrations of aldosterone were significantly 
higher in the control urine of women than in men.  
  Increased vascular oxidative stress may lead to alterations in endothelial function 
and may be related to hypertension [26]. The hypertensive effects of cocaine use are well 
established [36, 56]. Cocaine has been shown to activate the renin-angiotensin system 
(RAS) which contributes to its cardiotoxicity. ProANP is secreted from cardiac atria in 
response to myocyte strain and ischemia; increased levels of proANP have been observed 
in heart failure, left ventricular dysfunction, coronary artery disease, and renal failure 
[170]. The ANP pathway decreases blood pressure in response to hypertension [171]. 
Elevated proANP is considered predictive in renal failure, AMI and heart failure [172, 
173]. ProANP is cleared from the circulation in 60 to 120 minutes; it seems likely that 
there would not be a detectable amount in urine unless the specimen was collected within 
8 to 12 hours of the pathological insult. There were no significant differences in any 
analysis of proANP. 
  While it well known that cocaine affects the thermoregulating centers of the 
brain, it is unclear if this effect is exerted directly or via endogenous cytokines such as 
interleukins. IL-1α and IL-1β, acute phase response cytokines, are endogenous pyrogens 
capable of resetting the hypothalamus thermoregulatory center to change body 
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temperature [91, 174].  Our results suggest that cocaine may induce hyperexia through 
the interleukins. The cellular consequences of heat and ischemic stress are quite similar 
[175]. If cocaine exerted a significant thermogenic effect in our study following usage, 
IL-1α and IL-1β could be anticipated to be elevated in urine specimens of users. 
However, there were no significant differences between the urine of the control group 
versus the cocaine positive. Unfortunately, no information was available at the time of 
urine collection as to donor body temperature. Clearly, this is an important parameter that 
needs to be investigated further in a prospective study.  
 NGAL exists primarily as a monomer in neutrophils and urine; it also occurs as a 
complex with matrix metalloproteinase-9 (MMP-9). NGAL is expressed at a low level in 
other tissues including the kidney, prostate and epithelia of the respiratory and alimentary 
tracts. It is presently being investigated for validation as a biomarker of urinary tract 
infections [176]. NGAL is upregulated in processes that include apoptosis, ischemia, 
organogenesis and inflammation.  
 Increased levels of NGAL from acute renal injury can be detected in both urine 
and blood within two hours of the insult [57]. Taken in conjunction with its presence in 
urine and association with ischemia, NGAL may be a significant marker of cardiac 
dysfunction stemming from cocaine use [177-179]. Most cocaine-induced chest pains do 
not progress to AMI. The chest pains due to cocaine are induced by myocardial ischemia 
via vasospasm. Given the role of NGAL in oxidative and inflammatory processes, we 
were surprised not to see a difference in mean values of NGAL expression. The lack of 
statistically significant differences did allow us to tentatively rule out UTIs as the basis 
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for higher mean NGAL concentrations seen in female urine specimens. Coupled with the 
unlikelihood that the entire female cohort suffered from UTIs, the fact that male 
specimens had uniformly lower NGAL concentrations than did the females appears to 
suggest gender based expression differences. 
 Myoglobin lacks cardiospecificity; elevated levels are considered strongly 
suggestive of AMI – particularly in the presence of other symptoms. Elevated levels of 
myoglobin are also associated with rhabdomyolysis, renal failure and trauma [58].  
Myoglobin is released within 2 to 4 hours of significant myocardial and/or skeletal 
muscle injury. Levels peak 6 to 12 hours following the pathophysiological event; 
returning to prenecrotic levels within 36 hours. An estimated 24% of cocaine users 
develop rhabdomyolysis [58]. When male control urine specimens were compared to 
cocaine positive specimens, there was a statistically significant difference. 
The results of this study suggest there are gender-specific and cocaine-based 
differences in oxidative and inflammatory cytokine expression in urine. Males and 
females exhibit different morbidity and mortality across a wide range of conditions which 
suggests basic pathophysiology may control on the incidence of multiple disease 
processes.   
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Chapter 6.0 
Conclusions 
 
 
The purpose of this study was to investigate whether or not gender differences 
may be present in the expression of a number of urinary proteins which may serve as 
markers of inflammation and oxidative stress. It was concluded that the urinary 
expression of aldosterone, IL-1α and IL-1β appears to be influenced by gender.  Mean 
aldosterone (p=0.0223), IL1 α (p=.0007) and IL1 β (p=.0198) concentrations were 
significantly higher in female control urine when compared to male control urine. The 
results for hsCRP (p=.0662) and MPO (p=.0562) were also higher in female control urine 
when compared to male control urine; however, they did not reach statistical significance. 
The pathophysiological mechanisms associated with gender based differences in marker 
expression will require additional prospective study with expanded demographic 
information. 
 The urinary expression of aldosterone and myoglobin in males is influenced by 
the use of cocaine. There were statistically significant increases in myoglobin (p=.0095) 
and aldosterone (p=.0332) expression in the cocaine positive urine of males. Oxidative 
metabolites of cocaine generate significant ROS; much of the pathophysiological damage 
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associated with cocaine use stems from oxidative stress and electron transfer[32]. 
Cocaine use affects almost every organ system; myocardial infarction, arrhythmias, renal 
failure, hypertension, atherosclerosis, and rhabdomyolysis are all in the spectrum of acute 
and chronic cocaine toxicity [114, 115].   
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